Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 2 STUDY IDENTIFICATION 
Sponsor Cytokinetics, Inc.  
280 East Grand Avenue 
South San Francisco, California  94080 (650) 624-3000 (Main Telephone) (650) 624-3010 (Main Facsimile)  
Sponsor’s Study Contact Jacqueline Lee  
Director, Clinical Operations  
Cytokinetics, Inc.  
jlee@cytokinetics.com  
(650) 624-3017 (Office Telephone) (650) 291-5533 (Mobile Telephone)  
 Sponsor’s Medical Monitors Jinsy Andrews, MD, MSc Senior Director, Clinical Research & Development  
Head, Neuromuscular Therapeutics  
Cytokinetics, Inc.  
jandrews@cytokinetics.com (650) 243-1165 (Mobile Telephone)  Stacy Rudnicki, MD Director, Clinical Research & Development  
Cytokinetics, Inc.  
srudnicki@cytokinetics.com (650) 515-2524 (Mobile Telephone)  
(650) 624- 3225 (Office Facsimile)  
 
Lead Investigator  Jeremy Shefner, MD, PhD  
Professor & Chair of Neurology Barrow Neurological Institute  
jeremy.shefner@dignityhealth.org (315) 378-8531 (Mobile Telephone)  
 
Study Site  Multi-National 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 3 INVESTIGATOR PROTOCO L AGREEMENT PAGE 
 
I agree: 
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this protocol, any future amendments, and 
with any other study conduct procedures provided by Cytokinetics. 
• Not to amend the protocol without agreement, prior review, and written approval 
from the Institutional Review Board (IRB) , Research Ethics Board (REB), or Ethics 
Committee  (EC), except where necessary to eliminate an immediate hazard to the 
patients. 
• That I am thoroughly familiar with the appropriate use of the investigational 
product(s), as described in this protocol and any other information provided by the Sponsor including, but not limited to, the following: the current Investigator’s 
Brochure (IB) or equivalent document. 
• That I am aware of, and will comply with, “Good Clinical Practices” (GCP) and all 
applicable regulatory requirements.  
• To ensure that all persons assisting me with the stu dy are adequately informed about 
the Cytokinetics investigational product(s) and of their study- related duties and 
functions as described in the protocol. 
• That I have been informed that certain regulatory authorities require the Sponsor to obtain and supply, as necessary, details about the Investigator’s ownership interest in 
the Sponsor or the investigational product, and more generally about his/her financial ties with the Sponsor.  Cytokinetics will use and disclose the information solely for 
the purpose of complying with regulatory requirements. 
Hence I: 
Agree to supply Cytokinetics with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children); 
Agree to promptly update this infor mation if any relevant changes occur during the course of 
the study and for 1 year following completion of the study; and 
Agree that Cytokinetics may disclose any information it has about such ownership interests 
and financial ties to regulatory authoritie s. 
 
 
Investigator Name:  ______________________________________________________ 
 
Investigator Signature: ________________________________  Date: ________________ 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 4 TABLE OF CONTENTS  
STUDY IDENTIFICATION ...........................................................................................................2  
INVESTIGATOR PROTOCOL AGREEMENT PAGE  .................................................................3  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS ................................................10  
1. INTRODUCTION  ......................................................................................................13  
1.1. Background on Tirasemtiv .........................................................................................13  
1.2. Rationale for Tirasemtiv in the Potential Treatment of Amyotrophic Lateral 
Sclerosis ......................................................................................................................13  
1.3. Overview of Tirasemtiv Nonclinical Studies  .............................................................14  
1.4. Overview of Tirasemtiv Clinical Studies  ...................................................................15  
1.4.1.  Phase 1 and Phase 2a Studies .....................................................................................15  
1.4.2.  Phase 2b Clinical Trial in Patients with ALS (CY 4026; BENEFIT -ALS) ...............15  
2. STUDY OBJECTIVES  ..............................................................................................28  
2.1. Primary Objective  .......................................................................................................28  
2.1.1.  Primary Endpoint ........................................................................................................28  
2.2. Secondary Objectives  .................................................................................................28  
2.2.1.  Secondary Endpoints ..................................................................................................28  
2.2.2.  Tertiary Endpoints ......................................................................................................29  
3. STUDY OVERVIEW  .................................................................................................31  
3.1. Estimated Study Duration  ...........................................................................................34  
3.2. Tirasemtiv Dose Rationale  .........................................................................................34  
3.3. Rationale for the Open -Label Lead -In Phase Prior to Randomization .......................36  
3.4. Riluzole Dose Adjustment Rationale  ..........................................................................38  
3.5. Double-Blind, Placebo- Controlled, Tirasemtiv Withdrawal Phase Rationale  ...........39  
4. STUDY POPULATION  .............................................................................................41  
4.1. Inclusion Criteria  ........................................................................................................41  
4.2. Exclusion Criteria  .......................................................................................................41  
4.3. Additional Randomization Criterion  ..........................................................................42  
5. STUDY PROCEDURES  ............................................................................................43  
5.1. Screening  ....................................................................................................................43  
5.2. Open-Label Phase  .......................................................................................................43  
5.2.1.  WEEK -2 VISIT .........................................................................................................43  
5.3. Double-Blind, Placebo-Controlled Phase ...................................................................44  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 5 5.3.1.  DAY 1 VISIT  .............................................................................................................45  
5.3.2.  WEEK 2 VISIT  ...........................................................................................................46  
5.3.3.  WEEK 4 VISIT  ...........................................................................................................47  
5.3.4.  WEEK 8 VISIT  ...........................................................................................................48  
5.3.5.  WEEK 12 VISIT  .........................................................................................................49  
5.3.6.  WEEK 16 VISIT  .........................................................................................................50  
5.3.7.  WEEK 20 VISIT  .........................................................................................................51  
5.3.8.  WEEK 24 VISIT  .........................................................................................................53  
5.3.9.  WEEK 32 VISIT  .........................................................................................................54  
5.3.10.  WEEK 40 VISIT  .........................................................................................................55  
5.4. Double-Blind, Placebo-Controlled, Tirasemtiv Withdrawal Phase ............................56  
5.4.1.  WEEK 48 VISIT  .........................................................................................................57  
5.4.2.  WEEK 49 VISIT  .........................................................................................................58  
5.4.3.  WEEK 52 VISIT  .........................................................................................................59  
5.5. FOLLOW -UP VISIT (Week 56) ................................................................................59  
5.6. Visit Windows  ............................................................................................................60  
5.7. Timing of Doses .........................................................................................................61  
5.8. Concomitant Medications ...........................................................................................61  
5.9. PK Sample Collection  .................................................................................................62  
5.10.  Biomarker Sample Collection  .....................................................................................63  
5.11.  Clinical Safety Assessments  .......................................................................................64  
5.11.1.  Physical Examination  .................................................................................................64  
5.11.2.  Neurological Examination  ..........................................................................................64  
5.11.3.  Ashworth Score ..........................................................................................................64  
5.11.4.  Clinical Laboratory Evaluations .................................................................................64  
5.11.5.  12-Lead ECGs  ............................................................................................................64  
5.11.6.  Vital Signs  ..................................................................................................................64  
5.11.7.  Falls Assessment  .........................................................................................................64  
5.11.8.  Suicidality Assessment  ...............................................................................................64  
5.12.  Clinical and Pharmacodynamic Outcome Measures  ..................................................65  
5.12.1.  ALS Functional Rating Scale -Revised (ALSFRS -R) .................................................65  
5.12.2.  Respiratory Assessments  ............................................................................................65  
5.12.3.  Handgrip Strength  .......................................................................................................65  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 6 5.12.4.  Muscle Strength Measurements  ..................................................................................65  
5.12.5.  Quality of Life  ............................................................................................................65  
5.12.6.  Epworth Sleepiness Scale ...........................................................................................65  
5.12.7.  Caregiver Burden Assessment  ....................................................................................65  
5.13.  Patient Discontinuation from Study Participation  ......................................................65  
5.14.  Study Discontinuation ................................................................................................66  
5.15.  Safety Monitoring and Stopping Rules.......................................................................66  
5.16.  Data Monitoring Committee  .......................................................................................67  
6. INVESTIGATIONAL PRODUCT  ............................................................................68  
6.1. Description of Investigational Product .......................................................................68  
6.1.1.  Description of Riluzole or Placebo for Riluzole .........................................................68  
6.2. Dose Administration (Tirasemtiv or Placebo)  ............................................................69  
6.3. Dose Adjustment Criteria  ...........................................................................................69  
6.4. Treatment Interruption  ................................................................................................69  
6.5. Randomization Schedule and Removal of Blind ........................................................69  
6.6. Daily Dosing Diary  .....................................................................................................70  
6.7. Study Drug Handling and Disposal ............................................................................70  
6.8. Study Drug Accountability .........................................................................................70  
7. ADVERSE EVENTS AND S AFETY ASSESSMENTS  ...........................................71  
7.1. Definitions  ..................................................................................................................71  
7.1.1.  Adverse Event .............................................................................................................71  
7.1.2.  Serious Adverse Events ..............................................................................................72  
7.2. Adverse Event Severity  ..............................................................................................73  
7.3. Assessment of Causality to Study Treatment  .............................................................74  
7.4. Procedures for Eliciting and Recording Adverse Events ...........................................74  
7.4.1.  Eliciting Adverse Events  ............................................................................................74  
7.4.2.  Recording of Adverse Events  .....................................................................................74  
7.4.3.  Adverse Event Term  ...................................................................................................74  
7.4.4.  Recording Serious Adverse Events ............................................................................75  
7.4.5.  Pregnancy  ...................................................................................................................75  
7.5. Reporting Period for Adverse Events .........................................................................75  
7.5.1.  Follow-Up of Adverse Events ....................................................................................76  
7.6. Serious Adverse Events Require Immediate Reporting  .............................................76  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 7 8. STATISTICAL METHODS  .......................................................................................77  
8.1. General Considerations ...............................................................................................77  
8.1.1.  General Approach  .......................................................................................................77  
8.1.2.  Sample Size and Randomization ................................................................................77  
8.1.3.  Data Monitoring Committee  .......................................................................................78  
8.2. Analysis Sets  ...............................................................................................................78  
8.2.1.  Full Analysis Set (FAS)  ..............................................................................................78  
8.2.2.  Per Protocol Set (PPS)  ................................................................................................78  
8.2.3.  Safety Analysis Set (SAS)  ..........................................................................................78  
8.2.4.  Pharmacokinetic Evaluable Data Set (PKEDS)  .........................................................78  
8.3. Efficacy Endpoints ......................................................................................................78  
8.3.1.  Primary Endpoint ........................................................................................................78  
8.3.2.  Secondary Endpoints ..................................................................................................79  
8.3.3.  Tertiary Endpoints ......................................................................................................79  
8.3.4.  Additional Endpoints ..................................................................................................81  
8.4. Statistical Analyses  .....................................................................................................81  
8.4.1.  Patient Disposition  ......................................................................................................81  
8.4.2.  Demographics and Other Baseline Characteristics  .....................................................81  
8.4.3.  Primary Efficacy Analysis  ..........................................................................................81  
8.4.4.  Supportive Efficacy Analyses .....................................................................................82  
8.4.5.  Secondary and Tertiary Efficacy Analyses  .................................................................82  
8.4.6.  Other Supportive Efficacy Analyses ..........................................................................83  
8.4.7.  Additional Efficacy Analyses  .....................................................................................83  
8.4.8.  Hypothesis Testing and Multiplicity  ..........................................................................83  
8.4.9.  Sensitivity Analysis  ....................................................................................................83  
8.4.10.  Subgroup Efficacy Analyses .......................................................................................84  
8.5. Safety Analysis  ...........................................................................................................84  
8.5.1.  Adverse Events  ...........................................................................................................84  
8.5.2.  Other Safety Assessments  ...........................................................................................85  
8.5.3.  Suicidality Assessments ..............................................................................................85  
8.6. Study Drug Exposure ..................................................................................................85  
8.7. Concomitant Medication  ............................................................................................85  
8.8. Pharmacokinetic Analysis  ..........................................................................................86  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 8 8.9. Pharmacodynamic Analysis ........................................................................................86  
8.10.  Change in Statistical Methods  ....................................................................................86  
9. ADMINISTRATIVE ASPEC TS ................................................................................87  
9.1. Change in Protocol .....................................................................................................87  
9.2. Initiation Visit .............................................................................................................87  
9.3. Disclosure ...................................................................................................................87  
9.4. Monitoring ..................................................................................................................87  
9.5. Institutional Review Board / Ethics Committee / Research Ethics Board  ..................87  
9.6. Informed Consent .......................................................................................................88  
9.7. Records .......................................................................................................................88  
9.8. Reference to Declaration of Helsinki/Basic Principles  ..............................................88  
10. REFERENCES  ...........................................................................................................89  
APPENDIX A.  SCHEDULE OF EVENTS  ................................................................................90  
APPENDIX B.  SUBSTRATES OF CYP2B6 , 2C8, 2C9, AND 2C19 .......................................91  
APPENDIX C.  SUBSTRATES, INHIBITO RS AND INDUCERS OF CYP1A2  .....................92  
 
 
  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 9 LIST OF TABLES  
Table 1:  Exposure to Tirasemtiv  at the NOAEL in Rat and Dog .............................................14  
Table 2:  Estimated IC 50, kinact, and K I Values for Tirasemtiv  Time-Dependent 
Inhibition .....................................................................................................................15  
Table 3:  Percent Predicted Slow Vital Capacity in BENEFIT -ALS ........................................17  
Table 4:  Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  ...........................20  
Table 5:  Randomized Double-Blind Treatment Groups ...........................................................33  
Table 6:  Randomized Double-Blind, Tirasemtiv  Withdrawal Treatment  .................................33  
Table 7:  Distribution of Trough Tirasemtiv  Concentration at Steady -State by Dose  ...............35  
Table 8:  Visit Windows  ............................................................................................................61  
Table 9:  Pharmacokinetic (PK) Samples  ..................................................................................63  
Table 10:  Biomarker Samples  .....................................................................................................63  
Table 11:  Study Drug  ..................................................................................................................68  
Table 12:  Riluzole and Placebo for Riluzole ..............................................................................69  
Table 13:  Sample Size Re-estimation Depending on Common SD at Week 24 ........................78  
 
 
LIST OF FIGURES  
Figure 1: Changes from Baseline in Percent Predicted Slow Vital Capacity in 
BENEFIT-ALS ...........................................................................................................16  
Figure 2: Change from Baseline to Average after 8 and 12 Weeks in Percent Predicted Slow Vital Capacity  ....................................................................................................18
 
Figure 3: Study Design  ...............................................................................................................31  
Figure 4: First and Second Randomization ................................................................................32  
Figure 5: Predicted Steady -State Pharmacokinetic Profiles for Tirasemtiv  Target Dose 
Levels in CY  4031 ......................................................................................................35  
Figure 6: Incidence of Dizziness b y Double-Blind Treatment Assignment and Day of 
Double-Blind Treatment in CY 4024 .........................................................................36  
Figure 7: Steady-State Plasma Riluzole Exposur es with and without Steady- State 
Concomitant Tirasemtiv  at Total Daily Doses from 250 mg to 500 mg in 
BENEFIT -ALS ...........................................................................................................38  
 
 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 10 LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS  
Abbreviation  Explanation   
AE adverse event  
ALS amyotrophic lateral sclerosis  
ALT alanine aminotransferase (alanine transaminase)  
ALSAQ-5 ALS Assessment Questionnaire Short Form  
ALSFRS-R ALS Functional Rating Scale -Revised 
AM ante meridiem (morning)  
ANCOVA analysis of covariance  
ANOVA analysis of variance  
AST aspartate aminotransferase (aspartate transaminase) 
AUCinf  area under the concentration -time curve (extrapolated to infinity)  
AUC area under the plasma concentration -time curve (during dosing interval)  
BID twice a day  
BiPAP bilevel positive airway pressure  
BMI body mass index 
CBC Complete blood count (hematology clinical laboratory evaluations)  
CFR Code of Federal Regulations  
CI confidence interval  
CNS central nervous system  
CPAP continuous positive airway pressure  
CPK  creatine phosphokinase  
Cmax  maximum observed plasma concentration  
CTCAE Common Terminology Criteria for Adverse Events  
Ctrough pre-dose plasma concentration  
CYP cytochrome P 450 
DMC Data Monitoring Committee  
DPS diaphragm pacing system  
EC Ethics Committee  
ECG electrocardiogram  
eCRF electronic case report form  
EDC electronic data capture 
EudraCT European Union Drug Regulating Authorities Clinical Trials  
FAS full analysis set  
FDA Food and Drug Administration  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 11 Abbreviation  Explanation   
GCP Good Clinical Practices  
GI gastrointestinal  
GLP Good Laboratory Practices  
HEK human embryonic kidney  
hERG human ether -à-go-go related gene  
HHD hand-held dynamometry 
IB Investigator’s Brochure  
IC50 half maximal inhibitory concentration  
ICF informed consent form 
ICH  International C ouncil on Harmonisation  
IND investigational new drug  
INR international normalized ratio  
IRB Institutional Review Board  
IWRS Interactive Web Response System  
KI inactivation constant  
kinact  maximum rate constant for inactivation  
LFT liver function tests  
LSM least squares mean 
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram  
mL milliliter 
MTD  maximum tolerated dose  
MVIC Maximum Voluntary Isometric Contraction  
MVV   Maximum Voluntary Ventilation  
m2 meters squared  
NADPH nicotinamide adenine dinucleotide phosphate  
NCI National Cancer Institute  
NIPPV non-invasive positive pressure ventilation  
NOAEL no observed adverse effect level  
NYHA New York Heart Association  
PD pharmacodynamic  
PI Principal Investigator  
PK pharmacokinetic(s)  
PKEDS pharmacokinetic evaluable data set 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 12 Abbreviation  Explanation   
PM post meridiem (evening)  
PPS per protocol set  
QD once daily  
REB Research Ethics Board  
SAE serious adverse event  
SAS safety analysis set  
SD standard deviation  
SE standard error  
SNIP Sniff Nasal Inspiratory Pressure  
SVC slow vital capacity 
tmax time to maximum plasma concentration  
TDD total daily dose  
TEAE treatment -emergent adverse event  
TnC troponin C  
TSH thyroid stimulating hormone 
UA urinalysis  
ULN upper limit of normal  
WHO World Health Organization  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 13 1. INTRODUCTION 
1.1. Background on Tirasemtiv  
Tirasemtiv  (formerly CK -2017357) is a novel small molecule activator of fast skeletal muscle 
troponin, intended to improve skeletal muscle function in disease states associated with muscular 
weakness or fatigue, including amyotrophic lateral sclerosis ( ALS), without affecting the 
structure of muscle itself.  Tirasemtiv  selectively binds to the fast skeletal muscle troponin 
complex and slows the rate of calcium release from troponin C ( TnC).  This increases the affinity 
of TnC for calcium and thus sensitizes the sarcomere to calcium.  Tiras emtiv is selective for fast 
skeletal muscle troponin with little effect on slow skeletal muscle troponin and no effect on cardiac muscle troponin. By sensitizing the fast skeletal muscle troponin complex to calcium, tirasemtiv  shifts the calcium -force relationship of musc le fibers leftward, amplifying the 
response of muscle to submaximal nerve stimulation and thereby increasing muscle force.  Tirasemtiv  decreases  muscle fatigability in several preclinical models of exercise performance, 
presumably by reducing the energetic requirements of calcium cycling during muscle contraction  
(Russell, Hartman et al. 2012).  In a transgenic mouse model of ALS with functional deficits, 
single doses of tirasemtiv  significantly increased  submaximal isometric force, forelimb grip 
strength, grid hang time, and running performance on a rotating rod.  Additionally, diaphragm 
force and tidal volume were significantly higher ( Hwee, Kennedy et al. 2014 ).  Acute and 
reversible clinical  signs of intolerance were the dose- limiting toxicities in preclinical testing.  
The pharmacological profile of tirasemtiv  is unique in that it is a direct and selective functional 
activator of fast skeletal muscle; as such, it could benefit patients with a wide variety of disorders 
characterized by muscle weakness or fatigue.  
In a Phase 2b study that enrolled 711 patients with ALS (CY 4026, also known as BENEFIT-
ALS), 12 weeks’ treatment with tirasemtiv  was associated with statistically significant and 
potentially clinically meaningful reductions in the decline in slow vital capacity (SVC) versus 
placebo (see Section 1.4.2).  This observation is the basis for the current study, CY 4031.  
1.2. Rationale for Tirasemtiv  in the Potential Treatment of Amyotrophic 
Lateral Sclerosis 
Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement.  In ALS, progressive death of motor neurons leads to 
denervation of skeletal muscles.  Surviving motor units attempt to compensate for dying ones by 
innervating more muscle fibers ( a process called sprouting) but are only partially successful 
(Kiernan, Vucic et al. 2011). Over time, progressive denervation and its c onsequent skeletal 
muscle atrophy lead to weakness, fatigue, and eventually complete paralysis and death, primarily from respiratory complications.   
No curative therapies for ALS exist.  Rilutek
® (riluzole, Sanofi-Aventis U.S. LLC) is one of two 
medications approved for the treatment of ALS, and has a modest benefit on survival (Lacomblez, Bensimon et al. 1996). The other approved medication, Nuedexta
®, has a specific 
effect on em otional lability, a symptom experienced by a minority of ALS patients.  Two 
interventions that contribute greatly to the overall welfare and survival of ALS patients are the use of enteral feeding and ventilatory support. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 14 To date, there are no available tr eatments that can improve skeletal muscle function , and in 
particular  respiratory function.  B ecause tirasemtiv  has been demonstrated both to amplify 
skeletal muscle force production in response to diminished neuronal input and to delay the onset 
and reduce the magnitude of skeletal muscle fatigue during repeated or sustained efforts, it may be useful in the treatment of patients with ALS.  
1.3. Overview of Tirasemtiv  Nonclinical Studies  
A brief summary of the nonclinical safety and pharmacokinetics (PK) of tirasemtiv  is provided in 
this section.  Additional information concerning nonclinical assessments of the pharmacology, PK, and safety of tirasemtiv  is available in the Investigator’s Brochure (IB).  
Tirasemtiv  was evaluated in a series of Good Laboratory Practices (GLP) preclinical safety 
pharmacology and toxicology studies, including single- and repeat -dose toxicity studies 
performed in Sprague- Dawley rats up to 26 weeks and beagle dogs up to 39 weeks, teratology 
studies in rats and rabbits, single-dose phototoxicity studies in rats, and a core battery of genotoxicity tests.  
In rats, following administration of tirasemtiv  for 26 weeks at dose levels of 0, 5, 15 and 
30 mg/kg/day , target organ effects w ere observed at levels of 15 and 30 mg/kg/day and consisted 
of fibrosis and/or atrophy of the mandibular salivary glands and hepatocellular hypertrophy of 
the liver.  The finding in the liver was fully recovered and the findings in the salivary glands 
were partially recovered at 30  mg/kg/day following the recovery period.  The no observed 
adverse effect level (NOAEL) in  rats was considered to be 15 mg/kg/day in this study.  The 
exposures at the end of the study attained at the NOAEL are shown in Table 1 below. 
In dogs, administration of tirasemtiv  for 39 weeks at dose levels of 0, 6, 20 and 50 mg/kg/day  
resulted in adverse but reversible clinical signs at 50 mg/kg/day, non- adverse effects on body 
weight at all dose levels, and a decrease in food consumption at the high dose.  Tirasemtiv  
caused partially reversible increases in  aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) at 50 mg/kg/day, with  a reversible increased total bilirubin in females at 
50 mg/kg/day and a reversible increase in creatine kinase and aldolase activities in individual 
males and females at 50 mg/kg/day.  The NOAEL in dogs was considered to be 20 mg/kg/day in 
this study.
  The exposures at the end of the study attained at the NOAEL are shown in Table 1 
below. 
Table 1: Exposure to Tirasemtiv  at the NOAEL in Rat and Dog  
 26-Week Rat Toxicity Studies  
(NOAEL)  39-Week Dog Toxicity Studies  
(NOAEL)  
M F M F 
Dose (mg/kg/day) 15 15 20 20 
Cmax (μg/mL)  25.1 46.5 27.0 20.9 
AUC (μg•h/mL) 228.5 589.0 128.8 80.6 
There was no evidence of genotoxicity in bacterial reverse mutation, human lymphocyte 
chromosomal aberrati on, or rat micronucleus assays.  There was no evidence of phototoxicity in 
single-dose studies in rat or of embryolethality, fetotoxicity, or teratogenicity in rats and rabbits.  
Tirasemtiv  was observed to cause a reversible blockade of the hERG channel in human 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 15 embryonic kidney ( HEK) cells in vitro at 250 μM, but was less than 50% inhibitory .  Findings in 
cardiovascular, central nervous system  (CNS), and respiratory safety pharmacology studies of 
tirasemtiv  were not considered adverse because of their mild severity and/or limited duration. 
The potential of tirasemtiv  to inhibit cytochrome P450 (CYP) enzymes (CYP1A2, 2A6, 3A4, 
2B6, 2C8, 2C9, 2C19, 2D6, and 2E1) was studied in vitro  in human liver microsomes at 
concentrations up to 100 - 200 µM.  Both direct and time -dependent inhibitions were assessed. 
Tirasemtiv  did not inhibit CYP3A4, 2D6, 2A6, or 2E1 with half maximal inhibitory 
concentrations ( IC50s) exceeding the highest concentrations tested .  Tirasemtiv  was found to be a 
direct and time-dependent inhibitor of multiple CYP450 isoforms ( CYP1A2, 2B6, 2C8, 2C9, and 
2C19).  Kinetic parameters for the time -dependent inhibition, including the time -dependent IC50 
(inhibitory constant following 20 or 30 minute pre-incubation with microsomes + NADPH), 
maximum rate constant for inactivation (k inact) and inactivation constant (K I), are shown in 
Table 2. 
Table 2: Estimated  IC50, kinact, and K I Values for Tirasemtiv  Time-Dependent 
Inhibition  
CYP Isoform  Time-Dependent IC50 
(µM) kinact (min-1) KI (µM) 
CYP1A2 5.5 0.031 1.9 
CYP2B6 21 0.035 26 
CYP2C8 80 0.057 46 
CYP2C9 69 0.021 34 
CYP2C19  4 0.051 11 
1.4. Overview of Tirasemtiv  Clinical Studies  
1.4.1. Phase 1 and Phase 2a Studies  
Tirasemtiv  has been evaluated in three completed Phase 1  clinical trials in healthy volunteers 
(CY 4011, CY 4012 and CY 4013).  Three Phase 2 a clinical trials (CY 4021, CY 4024, and 
CY 4025) have been conducted in patients with ALS.  A Phase 2 a clinical trial in patients with 
claudication secondary to peripheral artery disease (CY 4022) and a Phase 2a clinical trial in 
patients with myasthenia gravis (CY 4023) ha ve also been completed.  The Phase 1  and Phase 2a 
clinical studies are summarized in Table 4.  Additional details are available in the IB. 
1.4.2. Phase 2b Clinical Trial in Patients with ALS (CY 4026 ; BENEFIT- ALS) 
CY 4026, also known as BENEFIT- ALS (Blinded Evaluation of N euromuscular E ffects and 
Functional I mprovement with T irasemtiv in ALS), was a Phase 2 b clinical trial in which 
711 patients with  ALS were enrolled from 73 centers in North America and Western Europe into 
open-label treatment with tirasemtiv  125 mg twice a day .  Subsequently, patients who completed 
one week of open-label treatment were randomized 1:1 to double- blind treatment with either 
tirasemtiv  (titrated at weekly intervals to each patient’s maximu m tolerated dose ≤ 250 mg twice 
daily) or placebo for 12 weeks .  Clinical assessments were made at baseline (i.e., prior to 
treatment with open -label tirasemtiv ), after 4, 8, and 12 weeks of double-blind treatment, and one 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 16 and four weeks after the last dos e of double- blind study drug.  Safety and efficacy were assessed 
among the 295 patients randomized to placebo who received at least one dose of double-blind 
study drug and the 301 patients randomized to tirasemtiv  who received at least one dose of 
double-blind study drug. 
The primary endpoint in BENEFIT-ALS, the mean change from baseline in the ALS Functional 
Rating Scale in its revised form (ALSFRS -R), was not statistically different between treatment 
groups. The least squares mean (LSM) changes from basel ine were −2.40 in the placebo group 
and −2.98 in the tirasemtiv  group. The LSM ± standard error (SE) difference between treatment 
groups (i.e., tirasemtiv  response minus placebo response) was −0.58 ± 0.366 (95% confidence 
interval (CI): −1.30, 0.14; p = 0.114).  Although BENEFIT-ALS did not achieve its primary 
efficacy endpoint, two pre- specified secondary endpoints, both reflective of skeletal muscle 
function, were positively impacted.   
Treatment with tirasemtiv  resulted in a statistically significant and potentially clinically  
meaningful reduction in the decline of vital capacity ( measured as SVC ) which assesses strength 
of the skeletal muscles responsible for breathing.  The percent predicted SVC declined -3.12 
percentage points (±0.90) from the baseline value over 12 weeks on tirasemtiv  compared to a 
decline of -8.66 percentage points (±0.80) in the placebo group (p= <0.0001).  This pre- specified 
secondary efficacy endpoint declined less on tirasemtiv  than on placebo at each assessment time 
point and this difference persisted throughout 28 days after discontinuation of double-blind 
treatment  (Figure 1, Table 3).  Vital capacity  has been shown to be an important predictor of 
disease progression and survival in prior clinical trials of patients with ALS.  
Figure 1: Changes from Baseline in Percent Predicted Slow Vital Capacity in 
BENEFIT- ALS 
 

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 17 Table 3: Percent Predicted Slow Vital Capacity in BENEFIT -ALS 
Slow Vital Capacity  Placebo 
(n = 210) Tirasemtiv  
(n = 178) All 
(N = 388) 
Baseline 
(prior to the one week Open- Label phase)  
(% Predicted, mean ± Standard Deviation 
[SD]) 89.7 (17.2) 85.7 (19.3) 87.8 (18.3) 
Time Point during the Double -Blind 
Treatment  Changes from Baseline  
(LSM ± SE)  p-value 
Week 4 -3.89 (0.62) -0.99 (0.68) 0.001 
Week 8 -5.81 (0.68) -2.85 (0.77) 0.004 
Week 12 -8.66 (0.80) -3.12 (0.90) <0.0001 
 Slope of decline  
(Percentage Points per day)   
Baseline to Week 12  -0.0905 -0.0394 0.0006 
 Changes from Baseline  
(LSM ± SE)   
Week 13 (1 week after last DB dose)  -8.03 (0.77) -3.75 (0.84) 0.0002 
Week 16 (4 weeks after last DB dose)  -10.30 (0.90) -5.39 (0.98) 0.0002 
As shown in Figure 2, tirasemtiv  reduced the decline in SVC compared to placebo regardless of 
age, gender, riluzole use, or body mass index ( BMI).  Subgroups with the largest and most 
significant differences in SVC on tirasemtiv  versus placebo (change from baseline to mean SVC 
after eight and 12 weeks of double-blind treatment) were: females (6.84%, p = 0.012); non- riluzole 
users (6.55%, p = 0.0005); and patients with baseline SVC ≥ median at baseline (6.02%, 
p < 0.0001).   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 18 Figure 2: Change from Baseline to Average after 8 and 12 Weeks in Percent Predicted 
Slow Vital Capacity  
 
The results of other secondary endpoints assessed in this trial were mixed.  The Muscle Strength 
Mega-Score, a measure of strength based on the percent change from baseline from several 
muscle groups in each patient, declined more slowly on tirasemtiv  versus placebo (p = 0.016 for 
the difference in slope of decline); however, there were no differences at any time point that 
reached statistical significance.  The rate of decline for Sniff Nasal Inspiratory Pressure (SNIP) 
was not statistically significantly different between tirasemtiv  and placebo (p  = 0. 21); however, 
SNIP decreased statistically significantly more on tirasemtiv  compared with placebo at four and 
12 weeks (p values at 4, 8, and 12 weeks were 0.012, 0.066, 0.050, respectively).  No differences in Maximum Voluntary Ventilation (MVV) and Hand Grip Fatigue were observed on tirasemtiv  
versus placebo.   
Serious adverse event s (SAEs) during double-blind treatment were more frequent on tirasemtiv  
than on placebo (9.0% vs. 5.4%).  The most common SAE was respiratory failure, which 
occurred in one patient on tirasemtiv  and three patients on placebo, while confusional state and 
delirium occurred in two patients on tirasemtiv  and no patients on placebo.  Of patients receiving 
at least one dose of double-blind study drug, more patients on tirasemtiv  withdrew from the trial 
following randomization than on placebo (97 vs. 26 patients, respectively).  A dverse event s 
(AEs) more common on tirasemtiv  than on placebo (> 10% difference) were dizziness (50.8% 
vs. 19.7%), fatigue (33.2% vs. 14.2%), and nausea (21.9% vs. 7.8%).   
Patients on tirasemtiv  lost more weight than patients on placebo (change from baseline to 
Week 12: -1.70 kg vs. -0.79 kg; p = 0.006).  Weight loss was significantly greater in patients 

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 19 with gastrointestinal (GI) AEs (e.g., nausea and decreased appetite) on either treatment.  
However, such AEs occurred more frequently on tirasemtiv  than on placebo (43.5% vs. 25.8%).   
The statistically significant effect to reduce the decline in vital capacity observed in 
BENEFIT -ALS is a unique finding that has not been observed in any prior, sizable clinical trial 
in ALS patients.  Vital capacity is a quantitative measure of respiratory muscle function in ALS 
and has been shown to predict disease progression in prior clinical trials.  The significant results 
on SVC demonstrated in BENEFIT-ALS show that tirasemtiv  has a biological effect.  The 
cardinal symptom of ALS that directly affects survival is weakness of the skeletal muscles 
necessary for respiration.  Therefore, the significant reduction in the decline in vital capacity 
seen in this trial over 12 weeks is clinically relevant to patients with ALS.  Furthermore, the difference in vital capacity (measured by SVC) between tirasemtiv  and placebo was maintained 
four weeks after discontinuation  of double- blind treatment.  This suggests that  tirasemtiv  may 
have a durable impact on this measure of respiratory function in patients with ALS.  These effects, if persistent over longer periods of time, suggest that tirasemtiv  may reduce progressive  
respiratory decline in patients with ALS.   Consequently, the current Phase 3  protocol, CY 4031, 
has been developed with the objective to confirm and extend the potentially beneficial effects of 
tirasemtiv  on SVC and muscle strength observed in BENEFIT -ALS. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 20 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  
Population 
Phase 
(Study #)  N Trial Design Results Start/End  
Start = First screened  
End = Last visit  
Healthy Male 
Volunteers 
Phase 1 
(CY 4011A) 
 57 • Double-blind, placebo -controlled; parallel 
dosing; tirasemtiv  vs. placebo 
• Determine safety, tolerability and PK of 
increasing single doses  
• Determine maximum tolerated dose (MTD) and plasma concentration  • Single doses up to 2500  mg administered  
– Solid active pharmaceutical ingredient in capsule: 20 mg to 1250 mg 
– Liquid suspension: 640 mg to 2500 mg 
• MTD determined to be 2000 mg ; mean C max = 
29.24 µg/mL  
• Median T max 5.0 hr for both formulations 
• Terminal t1/2 averaged 12.2 and 11.5 hours for 
the solid and liquid formulation, respectively  
• Dose proportional increase in  AUCinf over the 
dose range of 20 to 2500 mg 
• tirasemtiv  was generally well tolerated; no 
SAEs 07 May 2009 to     
17 Feb 2010  
 
Healthy Male 
Volunteers 
Phase 1 
(CY 4011B) 12 • Double-blind, randomized, placebo -
controlled 
• 4-period, cross- over; single doses of 250, 
500, 1000 mg and placebo in random 
order 
• Assess pharmacodynamic (PD) effects  
• Relate any effects observed to associated plasma concentrations 
 • Statistically significant increases versus placebo 
in peak force generated by the tibialis anterior 
muscle during transcutaneous stimulation of the 
common peroneal nerve that were related to 
nerve stimulation frequency and to tirasemtiv 
dose and plasma concentration  
• Tirasemtiv was generally well tolerated; no SAEs 
 07 Oct 2009 to      
21 Dec 2009
 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 21 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Healthy Male 
Volunteers 
Phase 1 
(CY 4012) 24 • Double-blind, randomized, placebo-
controlled 
• Once daily dosing for 7 days  
• Two cohorts, parallel dosing:  
– tirasemtiv  250 mg vs. placebo 
– tirasemtiv  375 mg vs. placebo 
• After multiple doses to steady-state: 
– Assess safety and tolerability  
– Evaluate the PK profile  
 • Dose proportional C max and AUC 24hr 
• Modest (~70%) accumulation from single -dose 
to steady-state 
– Mean C max of 6.34 and 8.22 µg/mL  after 
single doses of 250 mg and 375 mg, 
respectively  
– Mean C max of 9.13 and 13.39 µ/mL  after 
dosing to steady-state with 250 mg QD 
and 375 mg QD, respectively 
• Mean t 1/2 of 8.99 hr and 12.28 hr after dosing to 
steady-state with 250 mg QD and 375 mg QD, 
respectively  
• Systemic exposures were high; inter -subject 
variability was low  
• Tirasemtiv was generally well tolerated; no 
SAEs 28 Oct 2009 to      
17 Dec 2009  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 22 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Healthy Male or 
Female Volunteers  
Phase 1 
(CY 4013) 
 
 39 • Open-label, drug-drug interaction (DDI) 
and food effect study (2 part study) 
Part A  
• steady-state administration of tirasemtiv 
on the PK of single doses of riluzole 
Part B 
• steady-state administration of tirasemtiv 
on the PK of single doses of a warfarin 
+ rosiglitazone cocktail  
• effect of food on a single dose of tirasemtiv  
• safety and tolerability of multiple doses of tirasemtiv  Part A  
• Steady-state tirasemtiv  (250 mg) raised the 
mean C max of riluzole approximately 
2.04-fold, mean AUC inf approximately 
3.77-fold compared with riluzole alone 
• Mean t 1/2 of riluzole increased from 7.52 
hours to 14.72 hours in the presence of 
steady-state tirasemtiv  
• Co-administration of tirasemtiv  reduced the 
inter-subject variability of riluzole C max and 
clearance  
Part B 
• Analysis of PK data from Part B of the 
study indicated that the AUC inf for 
rosiglitazone and both S- warfarin and R -
warfarin increased approximately 2 -fold in 
the presence of steady -state plasma 
tirasemtiv  achieved by daily dosing at a 
dosage of 250 mg once daily  
• Food had no effect on t max, or AUC  
• Administration of a high -fat meal increased 
the Cmax of tirasemtiv by approximately 55%  15 Mar 2011 to      
27 Jun 2011  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 23 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Patients with ALS  
Phase 2a 
(CY 4021) 67 • Double-blind, randomized, placebo-
controlled 
• 3-period, crossover study  
• Single doses of tirasemtiv (250 mg, 500 
mg) and placebo • Single doses of tirasemtiv were safe and 
generally well tolerated  
• Dizziness, which was generally mild, was 
the most frequently reported and most 
clearly dose -related adverse event  
• Both patients and investigators perceived a dose- and concentration -dependent 
improvement in the patients’ overall status 
at 6 hours after dosing  
• Statistically significant improvement in Maximum Voluntary Ventilation (MVV) at 6 and 24 hours after a single 500 mg dose; 
Sniff Nasal Inspiratory Pressure (SNIP) also 
trended to increase  
• Trend to increase in sub -maximum grip 
strength endurance  
• Small but statistically significant increases in Maximum Voluntary Isometric 
Contraction (MVIC) strength of some but 
not all muscles studied 29 Mar 2010 to       
2 Nov 2010
 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 24 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened  
End = Last visit  
Patients with 
Claudication  
Phase 2a 
(CY 4022) 61 • Double-blind, randomized, placebo-
controlled  
• 3-period cross-over study  
• Single doses of tirasemtiv (375 mg, 750 
mg) and placebo; the protocol was 
amended to reduce the 750 mg dose to 500 mg • Single doses of 375mg and 500 mg were safe 
and generally well tolerated  
• Two patients experienced SAEs including 
severe dizziness, prompting a protocol 
amendment to reduce the 750 mg dose to 
500 mg   
• Statistically significant and dose -related 
increases in total calf muscle work assessed by 
heel raise testing  
• Statistically significant and dose -related 
decreases in 6 minute walk distance, possibly due to AEs  such as dizziness that interfered 
with performance of the test  
 28 May 2010 to     
31 Mar 2011  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 25 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit 
Patients with ALS  
Phase 2a 
(CY 4024) 49 • Double-blind, randomized, placebo-
controlled study to evaluate the safety and 
tolerability of 14 days dosing of tirasemtiv  
without and with the concomitant administration of riluzole 
• 14 days of once daily  oral dosing with 
tirasemtiv  or placebo 
• Four parallel treatment groups  
– Placebo 
– tirasemtiv  125 mg 
– tirasemtiv  250 mg 
– tirasemtiv  375 mg 
• Part A (no riluzole): 7-day washout of 
riluzole followed by 14 days of tirasemtiv  
or placebo 
• Part B: All patients took riluzole 50 mg 
once daily for 7 days before and d uring the 
14 days of double-blind, once daily tirasemtiv  or placebo • 49 patients treated  
– Placebo: 6 Part A, 7 Part B  
– tirasemtiv  125 mg: 6 Part A, 6 Part B 
– tirasemtiv  250 mg: 6 Part A, 6 Part B 
– tirasemtiv  375 mg: 6 Part A, 6 Part B 
• Tirasemtiv appeared to be safe and well 
tolerated at once daily  doses of 125 mg, 250 
mg, and 375 mg daily for 14 days 
• Plasma concentrations of tirasemtiv  were 
unaffected by co-administration with riluzole, while plasma concentrations of riluzole  
approximately doubled during co-administration with tirasemtiv  
• AEs and clinical outcome measures during 
treatment with tirasemtiv  appeared similar with 
or without co-administration of riluzole  50 mg 
daily 
• The most frequently reported adverse event was dizziness. Most episodes were mild in intensity and began and resolved early after 
initiation of treatment and during continued dosing 
• Encouraging trends to increase the ALS 
Functional Rating Scale- Revised score and 
MVV were observed  in patients treated with 
tirasemtiv Part A:                   
20 Jun 2011 to      
10 Nov 2011  
Part B:                   
05 Oct 2011 to      02 Mar 2012  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 26 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Patients with ALS  
Phase 2a 
(CY 4025) 27 • Double-blind, randomized, placebo-
controlled study to evaluate the safety and 
tolerability of 21 days dosing of tirasemtiv  
administered according to a twice-daily, dose titration regimen with the concomitant administration of riluzole
 
• 21 days of twice daily oral dosing with 
tirasemtiv  or placebo 
• Two parallel treatment groups  
– Placebo dose titration  
− Week 1: 1 tablet twice daily 
− Week 2: 1 tablet in the 
morning and 2 tablets in the 
evening 
− Week 3: 2 tablets twice daily  
– Tirasemtiv dose titration  
− Week 1: 125 mg twice daily  
− Week 2: 125 mg in the morning and 250 mg in the 
evening 
− Week 3: 250 mg twice daily  
• All patients took riluz ole 50 mg once daily 
for 7 days before and during the 21 days of 
double-blind, twice -daily dose titration 
with tirasemtiv  or placebo  • 27 patients treated   
– Placebo titration: 6  
– tirasemtiv  titration: 21  
• Tirasemtiv administered in the twice -daily, 
dose titration regimen studied appeared to be safe and well tolerated  
• 14 of 21 patients randomized to tirasemtiv  were 
titrated to tirasemtiv 250 mg twice daily and 
completed the study at that dose level  
• Dizziness was the m ost frequent adverse event, 
reported by 12 of 21 patients on tirasemtiv  
– Mild in 10 patients , moderate in 2 patients  
– Resolved during continued dosing in 6 patients 
• Encouraging trends to increase the ALS 
Functional Rating Scale- Revised score and 
MVV were observed in patients treated with 
tirasemtiv  18 Nov 2011 to     
16 Mar 2012  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 27 Table 4: Completed Phase 1 and Phase 2a Clinical Studies with Tirasemtiv  (Continued)  
Population 
Phase 
(Study #)  N Trial Design  Results Start/End  
Start = First screened   
End = Last visit  
Patients with 
Myasthenia Gravis  
Phase 2a 
(CY 4023)  32 • Double-blind, randomized, placebo-
controlled 
• 3-period cross-over study  
• Single doses of tirasemtiv (250 mg, 500 
mg) and placebo  
 • Single doses of tirasemtiv were safe and 
generally well tolerated  
• Dizziness, which was generally mild, was 
the most commonly reported adverse event  
• There were no premature terminations and 
no SAEs reported  
• Quantitative Myasthenia Gravis (QMG) 
score decreased in a dose- related fashi on 
• Forced Vital Capacity (FVC) increased 
versus placebo at 6 hours after dosing  
 29 Dec 2010 to        
10 Oct 2012 
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 28 2. STUDY OBJECTIVES  
2.1. Primary Objective  
The primary objective is to assess the  effect of tirasemtiv  versus placebo on respiratory function 
in patients with ALS .   
2.1.1. Primary Endpoint  
The primary endpoint is the change from baseline to Week 24 of the double-blind, placebo-
controlled phase in percent predicted SVC . 
2.2. Secondary Objectives  
Secondary objectives include: 
• Evaluation of alternative methods to assess the effect of tirasemtiv  versus placebo on 
percent predicted SVC  in patients with ALS  
• Assessment of the effect of tirasemtiv  versus placebo on other clinical measures related 
to the progressive decline in respiratory function in patients with ALS 
• Assessment of  the effect of tirasemtiv  versus placebo on measures of skeletal muscle 
function in patients with ALS  
2.2.1. Secondary Endpoints  
The following secondary endpoints will be analyzed in a closed testing procedure if the primary 
efficacy analysis is met as defined in  Section 8.4.3. 
• Change from baseline in the ALSFRS- R score of the three respiratory items of the 
ALSFRS-R (i.e., the sum of items 10,  11 and 12) at the end of 48 weeks of double-blind, 
placebo-controlled treatment 
• Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-
controlled treatment  
• Time to the first occurren ce of a decline from baseline in percent predicted SVC ≥20 
percentage points or the onset of respiratory insufficiency or death at the end of the 48 
weeks of double-blind, placebo- controlled treatment 
• Time to the first occurrence of a decline in SVC to ≤50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-
controlled treatment  
• Change from baseline in the ALSFRS -R total score to the end of 48 weeks of the double-
blind, placebo- controlled treatmen t 
• Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo- controlled treatment  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 29 2.2.2. Tertiary Endpoints  
Tertiary endpoints are presented grouped by their similarities to one another.  The  prospectively 
defined tertiary  endpoints listed below will be the subject of descriptive, exploratory analyses as 
defined in the Statistical Analy sis Plan.  Additional tertiary endpoints of interest may be added to 
the Statistical Analysis Plan.  
1. “Time to Event” analyses including: 
a. Time to the first occurrence of a decline in SVC to ≤ 50% predicted or the onset of 
respiratory insufficiency (defined as tracheostomy or the use of non- invasive 
ventilation for ≥ 22 hours per day for ≥ 10 consecutive days) or death during the first 
24 weeks of double-blind, placebo- controlled treatment 
b. Time to the first occurrence of a decline from baseline in percent predicted SVC 
≥ 10 percentage points or the onset of respiratory insufficiency or death during the first 24 weeks of double-blind, placebo -controlled treatment  
c. Time to the first occurrence of a decline from baseline in percent predicted SVC 
≥ 20 percentage points or the onset of respiratory insufficiency or death during the first 24 weeks of double-blind, placebo- controlled treatment  
d. Time to the first occurrence of a decline in the respiratory components of the 
ALSFRS-R (i.e., items 10, 11, and 12) or death during the first 24 weeks of double-
blind, placebo- controlled treatment  
e. Time to the first occurrence of a decline in either of th e ALSFRS -R items 11 or 12 or 
death during the first 24 weeks and during all 48 weeks of double-blind, placebo-controlled treatment  
f. Time to the first occurrence of a decline in either of the ALSFRS -R item 12 or death 
during the first 24 weeks and during all 48 weeks of double-blind, placebo-controlled treatment  
g. Time to the first occurrence of the first use of mechanical ventilatory assistance or 
death during the first 24 weeks of double-blind, placebo- controlled treatment 
In addition, each of the first three composite endpoints listed above will be analyzed with 
“first use of mechanical ventilatory assistance” in place of “respiratory insufficiency”.  
2. “Responder analyses” including: 
a. Proportion of patients with no decline from baseline in percent predicted SVC, free 
from respiratory insufficiency and alive during the first 24 weeks and during all 
48 weeks of double-blind, placebo- controlled treatment 
b. Proportion of patients with a decline from baseline ≤ 6 percentage points in percent 
predicted SVC, free from respiratory insufficiency and alive during the first 24 weeks 
and during all 48 weeks of double-blind, placebo- controlled treatment  
c. Proportion of patients with a decline from baseline ≤ 10 percentage points in percent 
predicted SVC, free fro m respiratory insufficiency and alive during the first 24 weeks 
and during all 48 weeks of double-blind, placebo- controlled treatment  
d. Proportion of patients with a decline from baseline ≤ 20 percentage points in percent predicted SVC, free from respiratory  insufficiency and alive during the first 24 weeks 
and during all 48 weeks of double-blind, placebo- controlled treatment  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 30 3. Change from baseline to 24 weeks of double-blind, placebo- controlled treatment in the 
following measures:  
a. ALSFRS-R total score  
b. ALSFRS-R score of the three respiratory subdomains of the ALSFRS- R 
(i.e., items  10, 11, and 12) 
c. Muscle strength  as determined by the mega- score of: 
• Elbow flexion (bilateral)  
• Wrist extension (bilateral)  
• Knee extension (bilateral)  
• Ankle dorsiflexion (bilateral)  
• Handgrip strength (bilateral)  
d. SNIP 
4. Slopes of the changes from baseline in percent predicted SVC, ALSFRS- R, mega-score 
of muscle strength, and SNIP: 
a. From baseline to 24 weeks of the randomized, double-blind, placebo-controlled phase  
b. From baseline to 48 weeks of the randomized, double-blind, placebo-controlled phase 
(excluding mega- score of muscle strength)  
c. From the end of 24 weeks of the randomized, double-blind, placebo-controlled phase to the end of the double-blind, randomized, placebo-controlled phase at 48 weeks  
5. Changes in percent predicted SVC, muscle strength mega-score, and SNIP from baseline 
to the end of Week 48 of the double-blind, placebo-controlled phase. 
6. Change in percent predicted SVC from baseline to the end of Week 12 of the double-
blind, placeb o-controlled phase. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 31 3. STUDY OVERVIEW  
CY 4031 is a multi-national, double-blind, randomized, placebo- controlled, stratified,  parallel 
group study with the selective fast skeletal muscle troponin activator,  tirasemtiv , in patients with 
ALS who can complete two  weeks of treatment with open -label  tirasemtiv  (125 mg twice daily ).  
Both patients who are currently taking riluzole  and those who are not will be enrolled in the 
study.  Patients taking riluzole  who are randomized to tirasemtiv  will have their riluzole  dose 
decreased to 50 mg/day (half the approved dose) in a double-blind fashion, since previous 
studies have demonstrated that administration of tirasemtiv  approximately doubles the exposure 
to concomitant riluzole . 
The study includes th ree phases (Figure 3); an open-label phase, a double-blind, placebo-
controlled phase, and a double-blind, placebo-controlled tirasemtiv  withdrawal phase. 
Following completion of two weeks of treatment with open- label tirasemtiv , patients will be 
randomized 3:2:2:2 to placebo and three different dose levels of tirasemtiv .   
Approximately 600 patients are expected to be enrolled in the open- label phase.  Appr oximately 
477 of the patients enrolled onto open- label treatment are expected to be randomized in the 
double-blind, placebo-controlled phase. 
Figure 3: Study Design  
 
Screening  
The screening and qualification period for the study will be no more than 14 days in duration.  
Once patients have completed screening and are considered eligible, they will be enrolled to receive open -label  tirasemtiv  for two weeks. 
Open-Label Phase  
Week -2 is the first study visit after screening.  At Week -2, patients will report to the study site 
to begin the open -label phase, which will last 14 days.  During the open- label phase, patients will 
take 1 tablet (125 mg) of tirasemtiv  twice daily .  Patients will be contacted by phone after seven 
days and return to the study site after 14 days of open- label treatment.  

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 32 Double-Blind, Placebo -Controlled P hase 
Day 1 is the beginning of the double-blind, placebo-controlled phase, which will last 
approximately 48 weeks.  Patients who have demonstrated a dequate tolerance of tirasemtiv  
during the open-label phase will be randomized to one of four study groups ( Figure 4) prior to 
the Day 1 procedures .  Patients in Groups 2, 3, and 4 will receive double-blind tirasemtiv  for the 
next 48 weeks and patients in Group 1 will receive matching placebo tablets in lie u of tirasemtiv  
(Table 5).   
During the double- blind, placebo-controlled phase , additional study visits will take place at the 
end of Week 2, Week 4, Week 8, Week 12, Week 1 6, Week 20, Week 24, Week 32, Week 40, 
and Week 48. 
Patients will not escalate their dose if signs of intolerability are present.  Patients who do not 
tolerate a dose escalation due to symptoms believed to be due to treatment with study drug will 
be returned to a previously tolerated dose level.  Decisions regarding dose escalation and de-
escalation will be made and executed in a manner that does not compromise blinding either to treatment or to dose level.  
Figure 4: First and Second Randomization 
 

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 33 Table 5: Randomized Double -Blind Treatment Groups  
Group 1 
(Placebo)  Group 2 
(target 250 mg/day of 
tirasemtiv ) Group 3 
(target 375 mg/day of 
tirasemtiv ) Group 4 
(target 500 mg/day of 
tirasemtiv ) 
Weeks 1 through 48 
2 placebo tablets twice 
daily to end of Week 48 Weeks 1 through 48 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of 
matching placebo in AM and 1 tablet of tirasemtiv  
(125 mg) and 1 tablet of matching placebo in PM  Weeks 1 and 2  
1 tablet (125 mg) of tirasemtiv  and 1 tablet of 
matching placebo in AM and 1 tablet of tirasemtiv  
(125 mg) and 1 tablet of matching placebo in PM  
Weeks 3 through 48 
1 tablet (125 mg) of tirasem tiv and 1 tablet of 
matching placebo in AM and 2 tablets of tirasemtiv  
(250 mg) in PM  Weeks 1 and 2  
1 tablet (125 mg) of tirasemtiv  and 1 tablet of 
matching placebo in AM and 1 tablet of tirasemtiv  
(125 mg) and 1 tablet of matching placebo in PM  
Weeks 3 an d 4 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of 
matching placebo in AM and 2 tablets of tirasemtiv  
(250 mg) in PM  
Weeks 5 through 48 
2 tablets (250 mg) of tirasemtiv  in AM and 
2 tablets of tirasemtiv  
(250 mg) in PM  
Riluzole  Users Only  
Group 1 
(Placebo)  Groups 2 -4 
(Active Treatment Groups)  
Riluzole tablets 
50 mg riluzole (personal 
supply) in the morning plus blinded riluzole 
50 mg in the evening  Riluzole tablets  
50 mg riluzole (personal supply) in the morning plus blinded riluzole placebo in th e 
evening 
Double-Blind, Placebo -Controlled Tirasemtiv  Withdrawal Phase  
Upon completion of the double-blind, placebo -controlled phase, patients will be randomized a 
second time ( Figure 4) to placebo or to continue their current active dose level of treatment in an 
allocation ratio of 1:1  for the next four weeks as part of the double-blind, placebo-controlled 
tirasemtiv  withdrawal phase ( Table 6).  Both the first and second randomizations will be 
stratified by  riluzole use/non-use.  
Table 6: Randomized Double -Blind, Tirasemtiv  Withdrawal Treatment  
Group 1 
(maintained on tirasemtiv ) Group 2 
(withdrawn to placebo)  
Weeks 49 through 52 
Maintained on the tirasemtiv  dose taken during the 
double-blind, placebo-controlled  phase Weeks 49 through 52 
Withdrawn  to or maintain  placebo dose in AM and PM  
During the double-blind, placebo-controlled, tirasemtiv  withdrawal  phase, additional study visits 
will take place at the end of Week 49 and Week 52.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 34 A final follow -up visit will occur four weeks after completion of the double-blind, placebo-
controlled tirasemtiv  withdrawal phase at Week 56 . 
Riluzole  
Patients who were not taking riluzole  prior to study entry will be encouraged not to take riluzole 
until they complete study drug dosing.  Patients who were not taking riluzole at study entry but who 
later decide to start riluzole during the dosing phase of the study will not be allowed to continue 
taking study drug. When patients are taking tirasemtiv  during the study, their dose of riluzole  will 
be reduced to 50 mg once daily in the morning as described in Section  5.8. 
3.1. Estimated Study Duration  
Individual patient participation will take place as follows:  
Screening 2 Weeks 
Open-Label Phase  2 Weeks 
Double-Blind, Placebo-Controlled  48 Weeks 
Double-Blind, Placebo-Controlled, Tirasemtiv Withdrawal 4 Weeks 
Follow Up  4 Weeks 
Total 60 Weeks 
3.2. Tirasemtiv  Dose Rationale  
In the Phase 2b study of tirasemtiv  in patients with ALS, BENEFIT -ALS, following a one week 
open-label run-in period at 250 mg/day, patients were titrated using weekly dose increases to 
their maximum tolerated dose  (MTD), up to 500 mg/day.  Flexible dosing was allowed to 
maximize tolerability.  Patients tended to drop out after titration from 250 mg/day to 375 mg/day 
and from 375 mg/day to 500 mg/day, suggesting that a longer titration schedule may improve tolerability.  Among patients on tirasemtiv  who completed the study, approximately half were on 
500 mg/day, and the remainder was divided generally equally between 375 mg/day and 250 mg/day.  Analyses of the change from baseline in percent predicted SVC on tirasemtiv  
versus placebo by MTD and tirasemtiv  exposure suggested that doses lower than 500 mg/day 
may still meaningfully reduce the decline from baseline in SVC in patients with ALS.  
Given the data from BENEFIT-ALS, we propose to evaluate further the relationship of specific tirasemtiv  doses to the inte nded effect to reduce the decline in respiratory function as measured 
by SVC while also attempting to improve the tolerability of tirasemtiv  with a more gradual dose 
titration schedule.  Thus, this study has been designed to test three separate target tirasemtiv  
doses (250 mg/day, 375 mg/day, and 500 mg/day), using a more gradual dose titration schedule 
than was employed in BENEFIT- ALS.  Patients who discontinue drug treatment will be expected 
to stay in the trial and complete all scheduled assessments.    
Figure 5 shows the range of tirasemtiv  concentrations associated with the steady -state PK 
profiles predicted to occur in CY 4031 based on data from BENEFIT -ALS and the tirasemtiv  
population PK model.  The solid lines represent the predicted average concentration -versus-time 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 35 profile and the upper and lower dashed lines represent the concentration-versus- time profiles at 
the 95th and 5th percentiles.   
Table 7 provides the distribution of AM and PM trough tirasemtiv  concentrations by dose level 
at steady-state.  
Figure 5: Predicted Steady-State Pharmacokinetic Profiles for Tirasemtiv  Target Dose 
Levels in CY 4031  
 
The black lines are for 125 mg BID, the blue lines are for 125 mg AM/  250 mg PM, and the red 
lines are for 250 mg BID, respectively.  
 
Table 7: Distribution of Trough Tirasemtiv  Concentration at Steady-State by Dose 
Parameters  125 mg BID  125 mg AM and 
250 mg PM 250 mg BID 
Trough prior to evening dose  
(µg/mL, median [5 -95 percentile] ) 5.4 [ 2.8 - 9.7 ] 7.1 [ 3.4 - 13 ] 9.9 [ 5 - 17.5 ] 
Trough prior to morning dose  
(µg/mL, median [5 -95 percentile] ) 5.4 [ 2.8 - 9.7 ] 8.2 [ 4.3 - 14.3 ] 9.9 [ 5 - 17.6 ] 
Trough prior to evening dose 
% of patients below 5/6/7/8 µg /ml  39.8/60.3/75.9/86  18/32.4/47.6/61.7  4.9/9.9/18/27.8  
Trough prior to evening dose 
% of patients above 13/14/15/16 µg /ml  0.4/0.3/0.2/0.2  5/2.8/1.8/1.2  22.2/16.4/12.1/9.2  0 5 10 15 200 5 10 15 20 25
Time (hour)Concentration (ug/mL)Steady state
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 36 3.3. Rationale for the Open -Label Lead -In Phase Prior to Randomization  
The open- label treatment phase for all patients prior to randomization to double-blind active 
tirasemtiv  versus placebo has been incorporated into the design of CY 4031 in order to diminish 
the potential for the occurrence of dizziness and other AEs  known to occur during treatment with 
tirasemtiv  to unmask the double- blind treatment assignment.   Open-label treatment at study onset 
also will serve to eliminate those patients unable to tolerate a dose of 125 mg of tirasemtiv  twice 
daily prior to randomization and inclusion in the intent to treat cohort. 
Treatment  with tirasemtiv  has been associated with a dose- related increase in reports of dizziness 
in both healthy volunteers and patients with ALS.  The dizziness is most often mild and usually 
resolves with continued dosing.  For example, the Phase 2 a study, CY 4024, 49 patients with 
ALS received two weeks’ treatment with once daily doses of placebo (n = 13) or tirasemtiv  at 
125 mg, 250 mg, or 375 mg (n = 12 for each group).  Dizziness was not reported on placebo in CY 4024 but occurred in 25%, 42%, and 50% of pa tients receiving tirasemtiv  at 125 mg, 
250 mg, and 375 mg once daily, respectively.  As shown below in Figure  6, among patients who 
reported dizziness, the symptom usually began early after the initiation of treatment and had mostly resolved by the second week. 
Figure 6: Incidence of Dizziness by Double- Blind Treatment Assignment and Day of 
Double-Blind Treatment i n CY 4024  
 
In another Phase 2 a study, CY 4025, 21 patients with ALS were randomized to receive double-
blind tirasemtiv  administered  as 125 mg twice daily for one week, followed by 125 mg in the 
morning and 250 mg in the evening during the second week, and 250 mg twice daily during the 
third and final week of treatment.  Another six  patients were randomized to a dummy dose 
titration with matching double -blind placebo.  None of the patients who received placebo in 
CY 4025 reported dizziness, while dizziness was reported by 12 of the 21 patients (57%) 
randomized to dose titration with active tirasemtiv .  Once again, among the 12 patients who 
reported dizziness, the symptom usually began early after the initiation of treatment.  In 10 of 
these 21 patients (48%), dizziness began during the first week of tirasemtiv  treatment at 

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 37 125 mg BID.  Of the 11 patients who did not experience dizziness during that first week of 
treatment, only two experienced its first onset during the second week, after up- titration to 
125 mg in the morning and 250 mg in the evening, and no patients in CY 4025 first experienced 
dizziness after titration to the highest dose of 250 mg twice daily.  Furthermore, in four of the 12 patients who reported dizziness at any time during CY 4025, the symptom resolved during 
continued administration of tirasemtiv , including up- titration to 250 mg twice daily and 
successful completion of the study in three patients. 
In summary, in CY 4024 and CY 4025, roughly half the ALS patients treated with tirasemt iv at 
daily doses of 250 mg and above reported dizziness, which generally began within the first few 
days of initiating treatment.  In many of these patients, however, dizziness tended to resolve with continued dosing, usually within a few days of its firs t occurrence.  
Due to concerns that the occurrence of dizziness and other AEs could contribute to the effective 
unblinding of patients in BENEFIT -ALS, all patients received one week of open-label treatment 
with tirasemtiv  125 mg BID prior to randomization to double-blind active tirasemtiv  versus 
placebo in an effort to diminish this potential for such unmasking of  the double- blind treatment 
assignment.  Roughly half the patients enrolled were expected to experience dizziness during 
open-label treatment with tirasemtiv  125 mg BID; however, if dizziness resolved after 
randomization to double-blind therapy, it could have been due to spontaneous resolution of the symptom despite continued treatment with active tirasemtiv  (as described above) or due to 
withdrawal of active tirasemtiv  and initiation of double-blind placebo. 
During BENEFIT -ALS, 291 of the 711 patients enrolled into the open-label portion of the study 
had at least one treatment -emergent adverse event (TE AE) of dizziness.  In these patients, the 
mean ± standard deviation ( SD) time to onset of the first episode of dizziness was 1.1 ± 
1.45 days (with a range of 0 to 10.4 days) and the mean ± SD duration of the first episode of dizziness was 14.7 ± 23.97 days (with a range of 0 to 121.4 days).  Among these 291 patients, 222 went on to be randomized to placebo or tirasemtiv .  Among the 111 of these 222 patients 
randomized to placebo, the mean ± SD duration of the first episode of dizziness that began during the open -label treatment was 14.2 ± 25.47 days (with a range of 0  to 121.4 days).  Among 
the 111 of these 2 22 patients randomized to tirasemtiv , the mean  ± SD duration of the first 
episode of dizziness that began during the open-label treatment was 20.0 ± 27.70 days (with a 
range of 0 to 113.6 days).  There is sufficient similarity  between these durations and their ranges 
to suggest that the week of open- label treatment with tirasemtiv  prior to randomization was 
generally effective in preventing dizziness on tirasemtiv  from unmasking the double-blind 
treatment assignment of an individual patient.   Consequently, an open-label phase prior to 
randomization has been retained in the design of the current study, CY 4031. 
Another purpose of open- label treatment with tirasemtiv  prior to randomization is to prevent 
randomization of patients who do not tolerate the starting dose of 125 mg BID.  In BENEFIT -
ALS, 16% of patients withdrew from open-label treatment prior to randomization; however, 
4.7% of patients randomized to tirasemt iv withdrew during the first week of double-blind 
treatment  (compared to 1.7% of patients randomized to placebo), even though the tirasemtiv  
dose during that first week was identical to the open- label tirasemtiv  dose regimen of 
125 mg BID.  Consequently, the duration of the open-label phase in CY 4031 has been increased 
to two weeks. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 38 3.4. Riluzole Dose Adjustment Rationale  
Tirasemtiv  is a mechanism -based inhibitor of the drug metabolizing enzyme CYP1A2, the major 
pathway of elimination for riluzole ; consequently, when tirasemtiv  is administered 
concomitantly with riluzole , plasma riluzole concentrations are increased relative to when 
riluzole is administered in the absence of tirasemtiv .  Consequently, in BENEFIT-ALS, patients 
taking riluzole  who were randomized to double-blind tirasemtiv  had their riluzole dose decreased 
from 50 mg twice daily  to 50 mg once daily in a double-blind manner as will be done in the 
current study, CY 4031 (described in  Section 5.8 Concomitant Medications). 
With the riluzole dose adjustment employed in BENEFIT -ALS, the analysis depicted in  
Figure 7, below, showed that during treatment with tirasemtiv  over the dose range to be studied 
in CY 4031 (i.e., 125 mg twice daily to 250 mg twice daily ), steady-state plasma riluzole 
concentrations at trough were not increased , while plasma riluzole  concentrations at one and 
three hours after dosing were increased by somewhat less than 2 -fold, and riluzole  AUC24h 
values were increased approximately 1.5-fold relative to when riluzole  was dosed in the absence 
of tirasemtiv .  Importantly, these steady -state riluzole exposures did not vary significantly with 
the total daily dose (TDD) of tirasemtiv  over the range from 250 mg to 500 mg.   
Figure 7: Steady-State Plasma Riluzole  Exposures with and without Steady -State 
Concomitant Tirasemtiv  at Total Daily Doses from 250 mg to 500 mg in 
BENEFIT- ALS 
 
The riluzole dose reduction employed in patients randomized to treatment with double -blind 
tirasemtiv  in BENEFIT- ALS did not completely adjust for the effect of tirasemtiv  to increase 
plasma riluzole concentrations when the two drugs were administered concomitantly.  As shown 
above, patients randomized to tirasemtiv  experienced somewhat  higher riluzole  exposures than 
patients randomized to placebo, despite the dose reduction.  Nevertheless, the riluzole dose 

Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 39 adjustment employed in BENEFIT -ALS will be implemented again in the current study, 
CY 4031, for the following reasons: 
1. Because riluzole is supplied only as 50 mg tablets, it is the only practicable dose 
adjustment for patients randomized to double-blind tirasemtiv  that preserves trough riluzole  
levels in the ranges observed in patients taking riluzole and double-blind placebo in 
BENEFIT -ALS.  Given the demonstrated benefits of riluzole  in the treatment of patients 
with ALS, it is important to err on the side of over-exposure rather than under-exposure. 
2. There were no differences in safety or tolerability observed between patients taking riluzole  
and those not taking riluzole in BENEFIT -ALS.  Differences in AE rates between the 
tirasemtiv  and placebo treatment groups were generally similar between patients taking 
riluzole and those not taking riluzole; furthermore, liver function tests (LFT) were similar  
in patients taking riluzole  and those not taking riluzole. 
Accordingly, patients who enter CY 4031 taking riluzole  will take half of the standard riluzole  
dose (i.e., 50 mg once daily) during the open- label phase and half of the standard riluzole  dose 
(i.e., 50 mg once daily) during the treatment phases when they are randomized to receive double-
blind tirasemtiv .  Patients who enter CY 4031 taking riluzole  and who are randomized to receive 
double-blind placebo will continue to receive the standard dose of 50 mg twice daily.  As noted 
elsewhere in this protocol ( see Section  5.8), the evening riluzole dose will be supplied by the 
study site during the placebo -controlled phases of the study in a double-blind fashion (active 
versus placebo riluzole) to preserve blinding of the randomization to tirasemtiv  versus placebo.  
In addition, because riluzole  exposure is frequently associated with elevations of LFT, LFT will 
be obtained after initiation of study drug and during dose escalation in CY 4031. 
3.5. Double-Blind, Placebo -Controlled, Tirasemtiv  Withdrawal Phase  
Rationale  
The double-blind, placebo-controlled, tirasemtiv  withdrawal phase has been incorporated into the 
design of CY 4031 in or der to evaluate the possibility of a “rebound effect” after 48  weeks of 
treatment with tirasemtiv ; i.e., increasing symptoms or loss of function after discontinuation of 
treatment to a point worse than if the patient had not received tirasemtiv .  This will be evaluated 
by comparing measures in those patients randomized to tirasemtiv  for the 48 weeks of double-
blind, placebo-controlled treatment but who were then randomized to placebo for the double-
blind, placebo-controlled, tirasemtiv  withdrawal phase to those randomized to placebo 
throughout the trial during clinic visits scheduled at Week 49 and Week 52.  At Week 49, 
clearance of tirasemtiv  should have essentially just completed among those patients who had 
received 48 week s of tirasemtiv , which is when rebound effects might be expected to be at their 
most prominent, should they occur.  The visit at Week 52 will allow assessment of the duration of such rebound effects (if any), or may document their resolution (again, should any such 
rebound effects be observed). 
Of note, there was no evidence for rebound worsening of symptoms or function after 
discontinuation of tirasemtiv  following 12 weeks of treatment in the Phase 2b study, BENEFIT-
ALS.  The assessment for rebound effects in CY 4031, however, will occur after 48 weeks of 
treatment with active tirasemtiv .  The substantially longer duration of tirasemtiv  treatment in 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 40 CY 4031 versus BENEFIT-ALS supports the inclusion of an assessment of rebound effects in 
CY 4031. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 41 4. STUDY POPUL ATION 
Approximately 600 patients who fulfill the eligibility  criteria will be enrolled in the study  and 
approximately 477 are expected to be randomized in the double-blind, placebo-controlled phase. 
4.1. Inclusion Criteria 
1. Able to comprehend and willing to sign an Informed Consent Form (ICF) 
2. Male or female 18 years of age or older  
3. A diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-
supported probable, probable, or definite criteria for a diagnosis of ALS according to the 
World Fe deration of Neurology El Escorial criteria)  ≤ 24 months prior to screening 
4. Upright SVC ≥ 70 % of predicted for age, height and sex 
5. Able to swallow tablets without crushing , and in the opinion of the Investigator, is 
expected to continue to be able to do so during the trial 
6. A caregiver if one is needed  
7. Clinical laboratory findings within the normal range or, if outside the normal range, 
deemed not clinically significant by the Investigator  
8. Male patients must agree for the duration of the study and 10 weeks after the end of the 
study to use a condom during sexual intercourse with female partners who are of 
childbearing  potential (i.e., following menarche until post-menopausal if not anatomically 
and physiologically incapable of becoming pregnant) and to have f emale partners use an 
additional effective means of contraception (e.g., diaphragm plus spermicide, or oral contraceptives) or the male patient must agree to abstain from sexual intercourse during 
and for 10 weeks after the end of the study, unless the mal e patient has had a vasectomy 
and confirmed sperm count is zero 
9. Female patients must be post-menopausal (≥ 1 year) or sterilized, or, if of childbearing potential, not be breastfeeding, have a negative pregnancy test, have no intention to become pregnant during the course of the study, and use effective contraceptive drugs or 
devices while requiring male  partner to use a condom for the duration of the study and for 
10 weeks after the end of the study 
10. Patients must be either on a stable dose of riluzole 50 m g twice daily for at least 30  days 
prior to screening or have not taken riluzole  for at least 30 days prior to screening and are 
willing not to begin riluzole  use until they complete study drug dosing 
4.2. Exclusion Criteria  
1. At the time of screening, a ny use of non-invasive positive pressure ventilation ( NIPPV, 
e.g. continuous positive airway pressure [ CPAP] or bi-level positive airway pressure 
[BiPAP]) for any portion of the day, or mechanical ventilation via tracheostomy, or on 
any form of oxygen supplementation 
2. Patients with a diaphragm pacing system (DPS) at study entry or who anticipate DPS 
placement during the course of the study 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 42 3. BMI of 20.0 kg/m2 or lower 
4. Unwilling or unable to discontinue tizanidine and theophylline- containing medications 
during study par ticipation  
5. Serum chloride outside the normal reference range 
6. Neurological impairment due to a condition other than ALS, including history of 
transient ischemic attack  within the past year  
7. Presence at screening of any medically significant cardiac, pulmonary, GI, 
musculoskeletal, or psychiatric illness that might interfere with the patient’s ability to 
comply with study procedures or that might confound the interpretation of clinical safety 
or efficacy data, including, but not limited to:  
a. Poorly controlled hypertension 
b. NYHA Class II or greater congestive heart failure  
c. Chronic obstructive pulmonary disease or asthma requiring daily  use bronchodilator 
medications  
d. GI disorder that might impair absorption of study drug  
e. History of significant liver disease defined by bilirubin > 2 times the upper limit of 
normal (ULN) or ALT or AST >  3 times the ULN on repeat testing   
f. Poorly controlled diabetes mellitus  
g. History of vertigo within three months of study entry 
h. History of syncope without an explainable or treated cause  
i. History of untreated intracranial aneurysm or poorly controlled seizure disorder  
j. Amputation of a limb  
k. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient’s ability to give informed consent and to understand and/or comply with study 
procedures  
l. Cancer with metastatic potential (other than basal cell carcinoma, carcinoma in situ of the cervix, or squamous cell carcinoma of the skin excised with clean margins) diagnosed and treated within the last two  years 
m. Any other condition, impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study 
n. Patient ju dged to be actively suicidal or  a suicide risk by the Investigator  
8. Has taken any investigational study drug within 30 days or five  half-lives of the prior 
agent, whichever is greater, prior to dosing 
9. Prior participation in any form of stem cell therapy for the treatment of ALS  
10. Previously received tirasemtiv  in any previous clinical trial 
4.3. Additional Randomization Criterion  
Patients must tolerate two weeks of open- label treatment with tirasemtiv  125 mg twice daily to 
be eligible for randomization.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 43 5. STUDY PROCEDURES  
5.1. Screening  
A signed ICF will be obtained prior to any screening procedures and before any study specific 
assessments are initiated.  
The following screening procedures will be performed for all potential patients at a visit 
conducted within 14 days  of start of the open-label phase of the study: 
1. Informed consent documentation  
2. Inclusion/exclusion criteria evaluation  
3. Demographic data collection  
4. Medical history collection  (includes smoking history) 
5. Clinical safety laboratory evaluations including a serum chemistry panel, complete blood count (CBC), urinalysis (UA), creat ine phosphokinase ( CPK), and thyroid stimulating 
hormone (TSH) 
6. Serum pregnancy test for females of child bearing potential  
7. Vital signs measurements (sitting for at least three minutes) including blood pressure, 
pulse, respiration rate and temperature  
8. 12-lead electrocardiogram ( ECG) 
9. Routine physical examination , including height and weight 
10. Neurological examination  
11. ALSFRS-R 
12. Respiratory  assessment  
13. Concomitant medication assessment 
14. Ashworth s core 
15. Suicidality assessment   
Confirmation of eligibility for enrollment into the open- label phase must occur prior to the 
Week -2 visit. 
5.2. Open-Label  Phase 
5.2.1. WEEK -2 VISIT 
Week -2 is the first study visit after screening  and the start of the open- label phase.  Patients will 
report to the study site for the Week -2 visit which may occur at any time up to, but not after 
14 days following the Screening Visit.  Patients will be instructed to bring their own riluzole 
supply to the study visit and not to take their morning dose of riluzole (for patients on riluzole) 
prior to arrival at the study site.   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 44 The following procedures will then be performed : 
1. PK blood sampling 
2. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK 
3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight   
4. Respiratory  assessment  
5. Handgrip strength (bilateral)  
6. Muscle strength measurement s 
7. ALSFRS-R 
8. ALS Assessment Questionnaire Short Form ( ALSAQ-5) 
9. Epworth Sleepiness Scale 
10. Falls assessment  
11. Caregiver Burden assessment  
12. AE evaluation and concomitant medication assessment (since last visit)  
13. Suicidality assessment   
Once the assessments are completed  at the Week -2 visit, patients will receive their first morning 
dose of open- label study drug (125 mg of tirasemtiv ).  Patients currently taking riluzole  also will 
take 50 mg riluzole from their personal supply. 
Patients will be given an adequate supply of open -label study drug ( tirasemtiv ) to take twice 
daily for 14  days at home until their  next clinic visit ( Day 1 Visit).  A diary will be provided for 
patients to record the date and time of twice daily study drug administration and riluzole  
administration (if on riluzole ).  Patients on riluzole  will be reminded to take 50 mg riluzole  from 
their personal supply at the same time as their morning dose of study drug and not to take their 
evening dose of riluzole during the open- label phase.   Patients will be contacted by phone after 
seven days of open- label tirasemtiv  and will return to the study site after 14 days of open- label 
treatment for the Day 1 visit.  
5.3. Double-Blind, Placebo -Controlled  Phase 
The double-blind, placebo -controlled phase will last approximately 48 weeks.  Patients who have 
demonstrated adequate tolerance of tirasemtiv  during the open- label phase will be randomized to 
tirasemtiv  versus placebo prior to the Day 1  procedures.  Randomization should occur following 
completion of the open- label phase and prior to Day 1 visit procedures.  Randomization must not 
occur until the patient has been contacted by study site personnel at the end of the open- label 
phase and  the Investigator is confident that the patient  has tolerated the open -label phase such 
that, if any a dverse symptoms that the patient experienced during open- label treatment were to 
continue throughout the double-blind portion of the study with the same severity, those 
symptoms would be sufficiently mild that they would not likely prevent the patient from 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 45 completing the study.  The patient , caregiver, and the I nvestigator will all be blinded to the 
patient’s treatment group assignment.   
5.3.1.  DAY 1 VISIT  
Day 1 marks the beginning of the  double-blind, placebo-controlled phase.  During the first two 
weeks of the double-blind, placebo-controlled phase, all patients will take a TDD of 250 mg of 
tirasemtiv  or placebo for 14 days .   
Patients will be instructed to bring their own riluzole supply to the study visit and not to take 
their morning dose of study dru g or riluzole (for patients on riluzole)  prior to arrival at the study 
site. 
The following assessments will be performed prior to administration of riluzole  and study drug 
while in the clinic: 
1. PK blood sampling 
2. Biomarker sample  
3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
4. Respiratory assessment    
5. ALSFRS-R 
6. Falls assessment  
7. AE evaluation and concomitant medication assessment (since last visit)  
8. Suicidality assessment   
Once all pre- dose procedures  have been performed at the Day 1 visit, patients will take their 
morning dose of assigned study drug (125 mg of tirasemtiv  or placebo).  For patients taking 
riluzole, 50 mg riluzole  from their personal supply should also be taken with the morning dose of 
study drug . 
Patients will begin double-blind dosing as follows for the next two weeks. 
Patients randomized to receive double-blind tirasemtiv :  
• Patients randomized to the TDD of 250 mg, 375 mg or 500 mg of tirasemtiv  will 
begin dosing with 1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in 
the morning and 1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in 
the evening for two  weeks 
Patients randomized to receive double-blind placebo will begin dosing with 2 placebo tablet s 
in the morning and 2 placebo tablet s in the evening for two  weeks. 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for two weeks  at home until their next clinic visit ( Week 2 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placeb o riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 46 will be reminded to tak e 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of study drug.    
5.3.2. WEEK 2 VISIT  
Patients will return approximately two  weeks later to the study site for the Week 2 visit.  Patients 
will be instructed  to bring their own riluzole supply to the study visit and not to take their 
morning dose of study drug or riluzole (for patients on riluzole)  prior to arrival at the study site.  
The following assessments will be performed prior to administration of riluzole  and study drug 
while in the clinic: 
1. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes, and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
2. Falls assessment  
3. AE evaluation and concomitant medication assessment (since last visit)  
4. Suicidality assessm ent  
Once all pre- dose procedures have been performed at  the Week 2 visit , patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.  
Patients will continue study drug dosing as follows for the next two weeks . 
Patients randomized to receive double-blind tirasemtiv :  
• For patients randomized to the TDD of 250 mg of tirasemtiv , patients will continue  
dosing with 1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the 
morning and 1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the 
evening for two weeks  
• For patients randomized to the TDD of 375 mg or 500 mg of tirasem tiv, patients will 
begin dosing with 1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in 
the morning and 2 tablets (250 mg) of tirasemtiv  in the evening for two weeks   
Patients randomized to receive double-blind placebo will continue dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for two weeks . 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for two weeks  at home until their next clinic visit ( Week 4 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same ti me as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of study drug.    
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 47 5.3.3. WEEK 4 VISIT   
Patients will return approximately two weeks later to the study  site for the Week 4 visit and 
continue with dosing .  Patients will be instructed to bring their own riluzole supply to the study 
visit and not to take their morning dose of study drug or riluzole (for patients on riluzole)  prior to 
arrival at the study site.  
The following assessments will be performed prior to administration of riluzole  and study drug 
while in the clinic: 
1. PK blood sampling 
2. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK  
3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
4. Respiratory assessment  
5. Handgrip strength (bilateral)  
6. Muscle strength measurements   
7. ALSFRS-R 
8. Ashworth score 
9. Falls assessment  
10. AE evaluation and concomitant medication assessment (since last visit)  
11. Suicidality assessment   
Once all pre- dose procedures have been performed at  the Week 4 visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.    
Patients will continue study drug dosing as follows for the next four weeks. 
Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
four weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for four weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will begin dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for four weeks   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 48 Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for four weeks . 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for four weeks at home until their next clinic visit ( Week 8 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same ti me as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of study drug.   
5.3.4. WEEK 8 VISIT  
Patients will return approximately four week s later to the study  site for the Week 8 visit and 
continue with dosing.  Patients will be instructed to bring their own riluzole supply to the study 
visit and not to take their morning dose of study drug or riluzole (for patients on riluzole)  prior to 
arrival at the study site.  
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. PK blood sampling 
2. Biomarker sample   
3. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK  
4. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
5. 12-lead ECG  
6. Respiratory assessment  
7. Handgrip strength (bilateral)  
8. Muscle strength measurements   
9. ALSFRS-R 
10. Ashworth score  
11. Falls assessment  
12. AE evaluation and concomitant medication assessment (since last visit)  
13. Suicidality assessment   
Once all pre- dose procedures have been performed at the Week 8 visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug. 
Patients will continue study drug dosing as follows for the next four weeks. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 49 Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
four weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for four weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablets (250 mg) of tirasemtiv  in 
the evening for four weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for four weeks . 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for four weeks at home until their next clinic visit ( Week 12 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of study drug .   
5.3.5. WEEK 12 VISIT  
Patients will return approximately four week s later to the study site for the Week 12 visit and 
continue with dosing.  Patients will be instructed to bring their own riluzole supply to the study 
visit and not to take their morning dose of study drug or riluzole (for patients on riluzole)  prior to 
arrival at the study site.  
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
2. Respiratory assessment  
3. Handgrip strength (bilateral)  
4. Muscle strength measurements  
5. ALSFRS-R 
6. ALSAQ-5 
7. Epworth Sleepiness Scale 
8. Ashworth score  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 50 9. Falls assessment  
10. AE evaluation and concomitant medication assessment (since last visit)  
11. Suicidality assessment   
Once all pre-dose procedures have been performed at the Week 12  visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of stud y drug. 
Patients will continue study drug dosing as follows for the next four weeks. 
Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
four weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasem tiv and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for four weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for four weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for four weeks .   
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for four weeks at home until their next clinic visit ( Week 16 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study drug.   
5.3.6. WEEK 1 6 VISIT  
Patients will return approximately four week s later to the study site for the Week 1 6 visit and 
continue with dosing.  Patients will be instructed to bring their own riluzole supply to the study 
visit and not to take their morning dose of study drug or riluzole (for patients o n riluzole)  prior to 
arrival at the study site.    
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. PK blood sampling 
2. Biomarker sample   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 51 3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
4. Respiratory assessment  
5. Handgrip strength (bilateral)  
6. Muscle strength measurements  
7. ALSFRS-R 
8. Falls assessment  
9. AE evaluation and concomitant medication assessment (since last visit)  
10. Suicidality assessment   
Once all pre-dose procedures have been performed at the Week 1 6 visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug. 
Patients will continue study drug dosing as follows for the next four weeks. 
Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
four weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg ) of tirasemtiv  in the evening for four weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for four weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for four weeks . 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twic e 
daily for four weeks at home until their next clinic visit ( Week 20 visit).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for pat ients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study drug.   
5.3.7. WEEK 20 VISIT  
Patients will return approximately four week s later to the study site for the Week 20 visit and to 
continue with dosing.  Patients will be instructed to bring their own riluzole supply to the study 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 52 visit and not to take their morning dose of study drug or riluzole (for patients on riluzole)  prior to 
arrival at the study site.    
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as  body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
2. Respiratory assessment  
3. Handgrip strength (bilateral)  
4. Muscle strength measurements  
5. ALSFRS-R 
6. Falls assessment  
7. AE evaluation and concomitant medicati on assessment (since last visit)  
8. Suicidality assessment   
Once all pre-dose procedures have been performed at the Week 20  visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug. 
Patients will continue study drug dosing as follows for the next four weeks. 
Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
four weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for four weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for four weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for four weeks . 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for four weeks at home until their next clinic visit ( Week 24 visit ).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 53 morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study visit.   
5.3.8. WEEK 24 VISIT  
The end of Week 24  marks the half way point in the double-blind, placebo-controlled phase .   
Patients will return approximately four  weeks later to the study site for the Week 24 visit and to 
continue with dosing.  Patients will be instructed to bring their own riluzole supply to the study 
visit and not to take their morning dose of study drug or riluzole (for patients on riluzole)  prior to 
arrival at the study site.    
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic:  
1. PK blood sampling 
2. Biomarker sample  
3. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK 
4. Serum pregnancy test for females of child bearing potential  
5. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
6. 12-lead ECG  
7. Respiratory assessment  
8. Handgrip strength (bilateral)  
9. Muscle strength measurements  
10. Routine physical examination  
11. Neurological examination  
12. ALSFRS-R 
13. ALSAQ-5 
14. Epworth Sleepiness Scale 
15. Ashworth score 
16. Falls assessment  
17. Caregiver burden  assessment  
18. AE evaluation and concomitant medication assessment (since last visit)  
19. Suicidality assessment  
Once all pre-dose procedures have been performed at the Week 24  visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 54 Patients will continue study drug dosing as follows for the next eight weeks . 
Patients randomized to receive double-blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
eight weeks  
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for eight weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for eight weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for eight weeks. 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for eight weeks at home until their next clinic visit ( Week 32 visit ).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study visit.    
5.3.9. WEEK 32 VISIT    
Patients will return approximately eight weeks later to the study site for the Week 3 2 visit.  
Patients will be instructed to bring their own riluzole supply to the study visit and not to take 
their morning dose of study drug or  riluzole (for patients on riluzole)  prior to arrival at the study 
site. 
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. PK blood sampling 
2. Biomarker sample   
3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
4. Respiratory assessment  
5. Handgrip strength (bilateral)  
6. Muscle strength measurements  
7. ALSFRS-R  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 55 8. Falls assessment  
9. AE evaluation and concomitant medication assessment (since last visit)  
10. Suicidality assessment  
Once all pre- dose procedures have been performed at the Week 32  visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.   
Patients will continue study drug dosing as follows for the next eight weeks. 
Patients randomized to receive double- blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
eight weeks 
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for eight weeks 
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for eight weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for eight weeks. 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for eight weeks at home until their next clinic visit ( Week 40 visit).  Patients takin g riluzole 
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg riluzole  from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study drug.   
5.3.10. WEEK 40 VISIT    
Patients will return approximately eight week s later to the study site for the Week 40  visit.  
Patients will be instructed to bring their own riluzole supply to the study visit and not to take 
their morning dose of study drug or  riluzole (for patients on riluzole)  prior to arrival at the study 
site. 
The following assessments will be performed prior to administration of morning dose of riluzole  
and study drug while in the clinic: 
1. PK blood sa mpling 
2. Biomarker sample   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 56 3. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investig ator will be alerted)  
4. Respiratory assessment  
5. Handgrip strength (bilateral)  
6. Muscle strength measurements  
7. ALSFRS-R  
8. Falls assessment  
9. AE evaluation and concomitant medication assessment (since last visit)  
10. Suicidality assessment  
Once all pre- dose procedures have been performed at the Week 40 visit , patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of stud y drug.   
Patients will continue study drug dosing as follows for the next eight weeks.  
Patients randomized to receive double- blind tirasemtiv : 
• Patients randomized to the TDD of 250 mg of tirasemtiv  will continue  dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the evening for 
eight weeks  
• Patients randomized to the TDD of 375 mg of tirasemtiv  will continue dosing with 
1 tablet (125 mg) of tirasemtiv  and 1 tablet of matching placebo in the morning and 
2 tablets (250 mg) of tirasemtiv  in the evening for eight weeks  
• Patients randomized to the TDD of 500 mg of tirasemtiv  will continue dosing with 
2 tablets (250 mg) of tirasemtiv  in the morning and 2 tablet s (250 mg) of tirasemtiv  in 
the evening for eight weeks   
Patients randomized to receive double-blind placebo will continue  dosing with 2 placebo 
tablets in the morning and 2 placebo tablet s in the evening for eight weeks. 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for eight weeks at home until their next clinic visit ( Week 48 visit ).  Patients taking riluzole  
will also be given a supply of double-blind riluzole or placebo riluzole  to take as the evening 
riluzole dose at home.  A diary will be provided for patients to record the date and time of twice 
daily study drug administration and riluzole  administration (if on riluzole ).  Patients on riluzole  
will be reminded to take 50 mg ri luzole from their personal supply at the same time as their 
morning dose of study drug and riluzole from the provided supply of double-blind riluzole  
(active or placebo) at the same time as their evening dose of  study drug .  
5.4. Double-Blind, Placebo -Controlle d, Tirasemtiv  Withdrawal Phase  
The double-blind, placebo -controlled, tirasemtiv  withdrawal phase will last approximately four 
weeks.  Upon completion of the double-blind, placebo -controlled phase, patients will be 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 57 randomized to continue active dosing or to withdraw from active treatment and receive placebo 
for the next four weeks.   
Randomization should occur following completion of the double-blind, placebo -controlled phase 
and prior to Week 48 visit procedures.  
5.4.1.  WEEK 48 VISIT  
The Week 48  visit marks the beginning of the  double-blind, placebo-controlled, tirasemtiv  
withdrawal phase.  Patients will be instructed to bring their own riluzole supply to the study visit 
and not to take their morning dose of study drug or riluzole  (for patients on riluzole)  prior to 
arrival at the study site.    
The following assessments will be performed prior to administration of the morning dose of 
riluzole and study drug while in the clinic: 
1. PK blood sampling 
2. Biomarker sample   
3. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK  
4. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient h as lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
5. 12-lead ECG  
6. Respiratory assessment  
7. Handgrip strength (bilateral)  
8. Muscle strength measurements  
9. Routine physical examination  
10. Neurological examination  
11. ALSFRS-R 
12. ALSAQ-5 
13. Epworth Sleepiness Scale 
14. Ashworth score   
15. Falls assessment  
16. Caregiver burden  assessment  
17. AE evaluation and concomitant medication assessment (since last visit)  
18. Suicidality assessment   
Once all pre-dose procedures have been performed at the Week 48  visit, patients wi ll take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 58 Patients will continue study drug dosing for the next four weeks based on the second 
randomization as follows ( refer to Figure 4): 
• Patients previously on double -blind tirasemtiv  and randomized to double-blind 
tirasem tiv will maintain the tirasemtiv  dose previously taken during the double-blind, 
placebo-controlled phase for the next four weeks.  
• Patients previously on double -blind tirasemtiv  and randomized to double -blind 
placebo will begin dosing with 2 placebo tablet s in the morning and 2 placebo tablet s 
in the evening for the next four weeks. 
• Patients previously on double -blind placebo will be randomized to continue to 
receive double-blind placebo with 2 placebo tablet s in the morning and 2 placebo 
tablets in the even ing for the next four weeks. 
Patients will be given an adequate supply of study drug ( tirasemtiv  or placebo) to take twice 
daily for four weeks at home.  Patients taking riluzole  will also be given a supply of double-blind 
riluzole or placebo riluzole  to take as the evening riluzole dose at home.  A diary will be 
provided for patients to record the date and time of twice daily study drug administration and 
riluzole administration (if on riluzole ).  Patients on riluzole  will be reminded to take 50 mg 
riluzole from their personal supply at the same time as their morning dose of study drug and 
riluzole from the provided supply of double-blind riluzole  (active or placebo) at the same time as 
their evening dose of study  drug.  
Patients will be reminded that even though they will receive a four week supply of study drug at 
this visit, they will need to return for a study visit (Week 49) following one week of treatment in the double-blind, placebo-controlled, tirasemtiv  withdrawal phase.   
5.4.2. WEEK 49 VISIT 
Patients will return approximately one  week later to the study site for the Week 49  visit.  Patients 
will be instructed to bring their own riluzole supply to the study visit and not to take their 
morning dose of study drug or riluzole (for patients on riluzole)  prior to arrival at the study site.    
The following assessments will be performed prior to administration of the morning dose of 
riluzole and study drug while in the clinic: 
1. PK blood sampling  
2. Vital signs measurements (including blood pressure, pulse, resp iration rate  after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
3. Respiratory  assessment   
4. Handgrip strength (bilateral)  
5. Muscle strength measurements  
6. ALSFRS-R 
7. Falls assessment  
8. AE evaluation and concomitant medication assessment (since last visit)  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 59 9. Suicidality assessment   
Once all pre-dose procedures have been performed at the Week 49 visit, patients will take their 
morning dose of assigned study drug.  For patients taking riluzole , 50 mg riluzole  from their 
personal supply should also be taken with the morning dose of study drug.  
Patients will continue study drug dosing as described in the Week  48 visit for the remaining three 
weeks of the double-blind, placebo-controlled, tirasemtiv  withdrawal phase.  Patients should be 
reminded to continue to record the date and time of twice daily study drug administration and 
riluzole administration (if on riluzole ) in their patient diary .  Patients on riluzole  will be 
reminded to take 50 mg riluzole  from their personal supply at the same time as their morning 
dose of study drug and riluzole from the provided supply of double-blind riluzole  (active or 
placebo) at the same time as their evening dose of study assignment.    
5.4.3.  WEEK 52 VISIT  
Patients will return approximately three  weeks later to the study site for the Week 52  visit.  
Patients will be instructed not to take their morning dose of  study drug or  riluzole (for patients on 
riluzole)  prior to arrival at the study site.   
The following assessments will be performed  while in the clinic:   
1. PK blood sampling 
2. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK 
3. Vital signs measu rements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
4. 12-lead ECG  
5. Respiratory assessment  
6. Maximum handgrip (bilateral)  
7. Muscle strength measurements  
8. ALSFRS-R   
9. Falls assessment  
10. AE evaluation and concomitant medication assessment (since last visit)  
11. Suicidality assessment  
The Week 52 visit represents the end of dosing.  Patients on riluzole will resume taking their 
prescribed 50 mg riluzole dose from t heir personal supply starting the evening of  the Week 52  
visit, and their prescribed 50 mg riluzole  twice daily starting the day after the Week 52 visit. 
5.5. FOLLOW-UP VISIT (Week 56)  
Patients will return to the study site approximately four weeks following the last dose of study 
drug taken during the double-blind, placebo-controlled, tirasemtiv  withdrawal phase, and the 
following final assessments will be performed:   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 60 1. Clinical Safety laboratory evaluations including serum chemistry panel, CBC, UA, and 
CPK  
2. Vital signs measurements (including blood pressure, pulse, respiration rate after sitting 
for at least three minutes , and temperature) as well as body weight  (if the patient has lost 
≥ 5% of body weight since baseline, the Investigator will be alerted)  
3. 12-lead ECG  
4. Respiratory  assessment  
5. Maximum handgrip (bilateral)  
6. Muscle strength measurements  
7. Routine physical examination    
8. Neurological examination  
9. ALSFRS-R 
10. ALSAQ-5 
11. Epworth Sleepiness Scale 
12. Ashworth score 
13. Falls assessment  
14. Caregiver burden assessment  
15. AE evaluation and concomitant medication assessment (since last visit) 
16. Suicidality assessment   
Upon collection of the assessments listed above, patients will have completed their participation 
in the study. 
5.6. Visit Windows  
To aid in scheduling patient visits, the following study visit windows are considered acceptable 
(Table 8).  If a patient  visit must be scheduled outside the visit window, the Medical Monitor 
should be contacted. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 61 Table 8: Visit Windows  
Visit Visit Window  
Week -4 Screening up to 14 days prior to Week -2 Visit (as per protocol)  
Week -2  14 days prior to Day 1 Visit, + 2 days 
Day 1 First day of randomized, double -blind dosing 
Week 2 +/- 2 days 
Week 4 +/- 2 days 
Week 8 +/- 4 days 
Week 12 +/- 4 days 
Week 16 +/- 4 days 
Week 20 +/- 4 days 
Week 24 +/- 4 days 
Week 32 +/- 7 days 
Week 40 +/- 7 days 
Week 48 +/- 7 days 
Week 49 +/- 1 day 
Week 52 +/- 3 days 
Week 56 Follow-Up 4 weeks after last dose, +/- 3 days 
5.7. Timing of Doses  
Study drug ( tirasemtiv  or placebo) should be taken in the morning at home (except on study visit 
days where it should be taken in the clinic) and in the evening, approximately 12 hours apart.  
Tirasemtiv  should be taken ≥ 2 hours after a meal or 1 hour prior to a meal.  For pat ients taking 
riluzole, tirasemtiv  may be taken at the same time as riluzole.  
5.8. Concomitant Medications  
All prescription drugs, over-the-counter medications, nutriceuticals and herbal remedies taken by the patient from the time of the screening visit through the follow-up visit should be entered into 
the electronic case report form  (eCRF). 
Patients who were intolerant to riluzole or chose not to take riluzole prior to study entry, will be 
encouraged not to take riluzole until they complete study drug dosing.  
Patients who were not 
taking riluzole at study entry but who later decide to start riluzole during the dosing phase of the 
study will not be allowed to continue taking study drug.  When patients are taking tirasemtiv  during 
the study, their dose of riluzole will be reduced to 50 mg once daily in the morning as described 
below. 
In order to preserve the blind with respect to assignment to tirasemtiv  versus placebo, patients 
taking riluzole  will take 50 mg riluzole  from their personal supply in the morning and during the 
placebo-controlled phases of the study (double-blind, placebo-controlled phase and the double-
blind, placebo-controlled tirasemtiv  withdrawal phase), a blinded (active or placebo) riluzole  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 62 tablet (supplied by the study site) in the evening .  Patients will resume taking their prescribed 
50 mg riluzole twice daily from their personal supply starting at Week 52. 
Thus, patients taking riluzole  prior to study entry will have their riluzole  adjusted, as follows: 
• During the open- label phase, patients  will take 50 mg riluzole  from their personal 
supply in the morning and will not take an evening riluzole dose.  
• During the double- blind, placebo-controlled phase (Day 1 – Week 48), patients will 
take their morning dose of riluzole  (50 mg once daily) and w ill take a blinded (active 
or placebo) riluzole  tablet (supplied by the study site) in the evening . 
• During the double- blind, placebo-controlled, tirasemtiv  withdrawal phase (Week 48 – 
Week 52), patients will take their morning dose of riluzole  (50 mg once daily)  and 
will take a blinded (active or placebo) riluzole  tablet (supplied by the study site) in 
the evening . 
• Patients will resume taking their prescribed 50 mg riluzole  twice daily from their 
personal supply starting at Week 52. 
Tirasemtiv  inhibits multiple CYP450 isoforms (1A2, 2B6, 2C8, 2C9, and 2C 19).  Consequently, 
exposure to drugs primarily metabolized by these isoforms  may be increased when these drugs 
are given in conjunction with tirasemtiv .  Therefore, close attention should be paid to potential 
AEs related to their administration.  For example, blood pressure should be closely monitored for 
hypertensive patients taking angiotensin II receptor blockers metabolized by CYP 2C9, such as 
losartan and irbesartan.  Diabetic patients taking oral anti -diabetic agents metabolized by 
CYP 2C8 or 2C9, including glyburide, glibencilamide, glipizide, glimepride and tolbutamide, 
should be cautioned to be aware of signs and symptoms of hypoglycemia, and serum glucose should be monitored as clinically appropriate.  Finally, caution should be exercised in the 
initiation of warfarin (also metabolized by CYP 2C9) if required during the study for the 
treatment of thromboses or thromboembolic events, with careful monitoring of prothrombin 
times and/or international normalized ratio ( INR).  A list of currently approved drugs 
metabolized by CYP 2B6, 2C8, 2C9, and 2C19 may be found in Appendix B . 
Patients must refrain from taking theophylline  or tizanidine , which are primarily metabolized by 
CYP 1A2 (see Section  1.3), during their participation in the study.  Additionally, patients should 
be advised to avoid or use caution when taking medications or ingesting other substances that are metabolized by CYP 1A2, such as fluvoxamine, because their metabolism is inhibited by 
tirasemtiv , so co-administration with tirasemtiv  will increase exposure to these compounds. 
Other medications that inhibit or induce the activity of CYP 1A2 may  increase or decrease, 
respectively, exposure to riluzole  which is metabolized by CYP 1A2.  Consequently, these drugs 
should be avoided by patients taking riluzole .  A list of currently approved drugs that interact 
with CYP 1A2 is found in Appendix C . 
5.9. PK Sample Collection   
Blood samples for PK analysis of tirasemtiv , and its acid metabolite,  CK-2018595, and riluzole  
(if the patient is taking riluzole ) will be collected at the time points listed in  Table 9.   The 
morning study drug and riluzole dose should be taken at the site on the se days.  Patients will be 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 63 instructed NOT  to take their morning dose of study drug or their dose of riluzole  until after the 
pre-dose PK blood draw.   
Table 9: Pharmacokinetic (PK) Samples  
Visit Sample Time Points  
Week -2  Pre-AM dose 
Day 1 Pre-AM dose 
Week 4 Pre-AM dose 
Week 8 Pre-AM dose 
Week 16 Pre-AM dose 
Week 24 Pre-AM dose 
Week 32 Pre-AM dose 
Week 40 Pre-AM dose 
Week 48 Pre-AM dose 
Week 49 Pre-AM dose 
Week 52 Pre-AM dose 
PK plasma samples remaining after completion of bioanalysis may also be used for exploratory 
analysis of tirasemtiv  metabolites.   These samples will NOT be used for pharmacogenomic or 
other testing.  
5.10. Biomarker  Sample Collection   
Biomarkers are objective measures or indicators of normal biological processes, pathological 
processes or pharmacological responses to a therapeutic intervention.  Biomarker development may be useful in developing markers to identify disease subtypes, to guide therapy, or predict 
disease severity.  Where authorized by the applicable IRB/EC/REB approved informed consent, 
blood samples for biomarker development will be collected at the time points shown in Table 10.   
 Table 10: Biomarker Samples  
Visit Sample Time Points  
Day 1 Pre-AM dose 
Week 8 Pre-AM dose 
Week 16 Pre-AM dose 
Week 24 Pre-AM dose 
Week 32 Pre-AM dose 
Week 40 Pre-AM dose 
Week 48 Pre-AM dose 
Plasma samples will be stored for future biomarker analyses and will NOT be used for 
pharmacogenomic testing.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 64 5.11. Clinical Safety Assessments  
5.11.1. Physical Examination 
A routine physical exam will be performed at Screening, Week 24, Week 48, and the Follow- Up 
Visit.   
5.11.2. Neurological Examination 
The neurological exam will be administered as described in the study manual and will include an 
assessment of cranial nerve functi on (including extra-ocular movements), motor strength, and 
sensory function. 
A neurological exam will be performed at Screening, Week 24, Week 48, and the Follow- Up 
Visit.  
5.11.3. Ashworth Score 
The Ashworth Score will be assessed as described in the study manual at Screening, Week 4 , 
Week 8, Week 12 , Week 24, Week 48  and the Follow- Up Visit. 
5.11.4. Clinical Laboratory Evaluations 
Clinical safety laboratory evaluations (serum chemistry panel, CBC, UA,  and CPK) will be 
collected at Screening, Week -2, Week 4, Week 8, Week  24, Week 48 , Week 52, and the Follow-
Up Visit.  A TSH will be collected only at the Screening visit  and a serum pregnancy test for 
females of child bearing potential  will be collected at Screening and the Week 24 visit.    
5.11.5. 12-Lead ECGs  
A 12-lead ECG will be obtained at Screening , Week 8, Week 24, Week 48, Week 52, and the 
Follow-Up Visit. 
5.11.6. Vital Signs  
Vital signs measurements (including blood pressure, pulse, respiration rate after sitting for at 
least three minutes , and temperature ) as well as body weight  will be recorded at all study visits.  
5.11.7. Falls Assessment  
A fall is defined as a sudden, unintentional change in position causing an individual to land at a 
lower level on an object, the floor, the ground, or other surface.  For the purposes of this study, the definition of a fall does not include stumbles or trips from which the patient rights 
him/herself without landing lower than his/her previous position ( Tinetti, Baker et al. 2004).  A 
falls assessment will be performed at each cl inic visit, starting at Week -2 through the final 
Follow-Up Visit.   
5.11.8. Suicidality  Assessment  
The suicidality assessment will be assessed as  described in the study manual at all study visits.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 65 5.12. Clinical and Pharmacodynamic Outcome Measures  
5.12.1. ALS Functional Rating Scale -Revised (ALSFRS -R)  
The ALSFRS -R will be administered as described in the study manual at all study visits  except 
Week 2.  When a patient does  not present in person for a scheduled visit, every attempt should be 
made to obtain the ALSFRS-R score by telephone as described in the study manual. 
5.12.2. Respiratory Assessment s 
The respiratory  assessments in this study include SVC and SNIP .  They will be performed as 
described in the study manual at every study visit except Week 2 .  
5.12.3. Handgrip Strength  
Maximum handgrip strength will be measured bilaterally  as described in the study manual at 
every study visit except Screening, Day 1, and Week 2 .   
5.12.4. Muscle Strength Measurements  
Muscle strength measurements (elbow flexion, wrist extension, knee extension, and ankle 
dorsiflexion) will be performed using the Hand Held Dynamometer (HHD), as described in the 
study manual at every study visit except Screeni ng, Day 1 , and Week 2 .   
5.12.5. Quality of Life  
The ALS Assessment Questionnaire Short Form ( ALSAQ-5) will be  used to assess the patient’s 
overall sense of well -being as described in the study manual at Week -2, Week 12, Week 24, 
Week 48, and the Follow- Up Visit. 
5.12.6. Epworth Sleepiness Scale  
The Epworth Sleepiness Scale will be assessed as described in the study manual at Week -2, 
Week 12, Week 24, Week 48 and the Follow- Up Visit. 
5.12.7. Caregiver Burden Assessment  
Caregiver burden will be assessed as described in the study  manual at Week -2, Week 24, 
Week 48, and the Follow- Up Visit. 
5.13. Patient Discontinuation from Study Participation  
Patients will be informed that they are free to withdraw from the study at any time and for any 
reason.  The Investigator may remove a patient from the study at any time if, in the Investigator's 
opinion, it is not in the best interest of either the patient or the study for the patient to continue in 
the study.  For those patients who will not return to the study center for further study scheduled 
assessments as described below, the Follow-Up Visit (Week 56) study assessments should be 
performed and recorded.  Notification of discontinuation will immediately  be made to the 
Sponsor’s Medical Monitor. 
In all cases, patients who were randomized and  discontinue study drug should be strongly 
encouraged to perform all remaining  study visits and assessments for the duration of the study 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 66 and most importantly the assessments at 24 weeks rather than withdraw from the study.  Unless 
patients withdraw their consent for further contact, those patients who are unable to attend 
scheduled study visits, should be contacted on a monthly basis to obtain vital status and 
respiratory status (i.e., use of non- invasive ventilation or permanent mechanical ventilation) 
through 48 weeks.   
The date the patient is withdrawn from study drug treatment  or study participation and the 
reason(s) for discontinuation will be recorded on the patient’s eCRF.  See Se ction 7.5.1 
regarding follow-up of AEs (both non-serious and serious) continuing at the time of study 
discontinuation.   
5.14. Study Discontinuation  
An Investigator may discontinue the participation of his/her study site, or the entire study may be 
discontinued at the discretion of the Sponsor, based on the occurrence of the following: 
• AEs  
• medical or ethical reasons affecting the continued performance of the study 
• difficulties in the recruitment of patients  
• cancellation of drug development 
5.15. Safety Monitoring and Stopping Rules  
Individual AEs meeting any of the following criteria will be reviewed by  the head of Drug Safety 
and the Sponsor’s Medical Monitor in a blinded manner on a periodic basis: 
1. SAEs thought by the Sponsor or the Investigator to be related to study drug 
administration  
2. Withdrawals due to AEs  (both serious and non-serious) 
3. Grade 3 or 4 (according to Common Terminology Criteria for Adverse Events  [CTCAE 
version 4.0], see Section 7.2) non-serious AEs  thought by the Sponsor to be related to 
study drug administration  
4. Any death thought by the  sponsor or the investigator to be related to study drug will 
result in stopping all randomization in order to perform a review.   
This review may result in:  
• Discontinuation of the study 
• Discontinuation of enrollment at the affected and higher dose levels 
• Modification to study conduct, or 
• No change to the conduct of the study (if AEs  are determined to have been unrelated 
to study drug administration) 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 67 5.16. Data Monitoring Committee  
An independent Data Monitoring Committee ( DMC) will periodically assess patient safety in an 
unblinded manner during the course of the study.  No unblinded data will be accessible to site 
staff, the Sponsor, study monitors, and personnel of the electronic data capture (EDC) vendors 
before the database is locked.   
The specific activities and responsibilities of the DMC are defined in the DMC Charter for 
CY 4031. Based on the totality of available data, the DMC will make an overall recommendation 
to the Sponsor whether to continue the study according to the protocol or whether to make any 
changes in study conduct to protect the safety and welfare of the patients participating in the 
study.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 68 6. INVESTIGATIONAL PRODUCT  
6.1. Description of Investigational Product  
This is a double-blind, placebo-controlled study.  As such, the site pharmacy staff, the 
Investigator, the patient, and remaining study site clinical staff will be blinded  to treatment 
assignment . 
CK-2017357 (tirasemtiv ) study drug  is supplied as immediate release , white, modified oval 
tablets at a dose strength of 125 mg of tirasemtiv  per tablet , which are to be stored under secure 
conditions at controlled room temperature (20-25°C; 68-77°F) with temporary excursions 
allowed between 15-30°C; 59-86°F.  Matching placebo tablets will be supplied and should also 
be stored at controlled room temperature under secure conditions.  Active CK -2017357 t ablets 
contain 125 mg  of tirasemtiv  plus excipients.  Placebo tablets contain excipients only.   
Table 11: Study Drug  
Study Drug  CK-2017357 Placebo for CK -2017357  
Form Tablet Tablet 
Supplier Cytokinetics, Inc. Cytokinetics, Inc. 
Manufacturer  Patheon, Inc. Patheon, Inc. 
CK-2017357 ( tirasemtiv ) and matching placebo tablets will be supplied to the clinical site in 
blister strips inside labeled wallets.  During the open -label phase of the study, patients will 
receive a bottle containing 40 tablets of tirasemtiv , sufficient for two weeks  of dosing plus 
overage.  Open-label bottles will be labeled with a lot number .  During the double-blind 
randomized phases of the study, patients will receive one or more wallets containing 72 tablets of 
study drug ( tirasemtiv  or matching placebo) at each visit.  Each wallet is sufficient for two weeks 
of dosing, plus overage.  Double-blind wallets will be labeled with a unique random kit number.   
The site pharmacist or other qualified person responsible for managing study drug supplies will 
maintain an accurate record of the receipt of the investigational study drug as shipped by the 
Sponsor (or designee), including the kit number and date received.  One copy of this receipt will 
be returned to the Sponsor when the contents of the investigational study drug shipment have 
been verified.  The study research coordinator or designated site staff will be responsible for 
patient randomization s, using an IWRS.  In addition, an accurate drug disposition record will be 
kept, specifying the kit number provided to each patient and the dates of dose administration.  
This drug accountability record will be available for inspection at any time.  At the completion of 
the study, the original drug accountability record will be available for review by the Sponsor upon request. 
All unused drug supplies will be returned to the Sponsor (or designee) or disposed of by the 
study site, per the Sponsor’s (or designee’s) instructions at the end of the study. 
6.1.1. Description of Riluzole or Placebo for Riluzole  
This is a double-blind, placebo-controlled study.  As such, the site pharmacy staff, the 
Investigator, the patient, and remaining study site clinical staff will be blinded  to riluzole  or 
placebo treatment.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 69 Riluzole and matching placebo will be supplied as white, capsule shaped tablets .  One riluzole 
tablet will contain  50 mg riluzole  plus excipients.  Placebo tablet s for riluzole will contain 
excipients only.  Riluzole  and matching placebo tablets are to be stored under secure conditions 
at controlled room temperature (20 -25°C; 68-77°F) with temporary excursions allowed between 
(15-30°C; 59-86°F).   
Table 12: Riluzole and Placebo for Riluzole 
Study Drug  Riluzole Placebo for Riluzole   
Form Tablet Tablet 
Supplier Cytokinetics, Inc. Cytokinetics, Inc. 
Manufacturer  Almac Clinical Services, LLC  Almac Clinical Services, LLC  
Riluzole and placebo for riluzole will be supplied to the clinical site in  blister strips inside 
labeled wallets.  Patients will receive one or more wallets, containing 18 riluzole  or placebo for  
riluzole  tablets at each visit.  Each wallet is sufficient for two weeks  of dosing, plus overage.  
Double-blind wallets will be labeled with a unique random kit number.  
6.2. Dose Administration ( Tirasemtiv  or Placebo)  
This study drug will be administered orally as tablets to patients with ALS.  Doses ( tirasemtiv  or 
placebo) for each of the treatment groups will be dispensed in accordance with the study 
randomization prior to the patient’s first dose. 
6.3. Dose Adjustment Criteria 
Patients who do not tolerate a dose escalation due t o symptoms believed to be due to treatment 
with study drug may be returned to a previously tolerated dose level  at the discretion of the 
Investigator.  No upward dose adjustments will be allowed subsequent to a dose reduction. 
6.4. Treatment Interruption  
Patients who do not take the total assigned daily dose of study drug due to conditions of 
hospitalization or other circumstances should be encouraged to return to treatment.  The Medical 
Monitor should be contacted for a patient  who has discontinued treatment for more than one 
week. Specific instructions regarding treatment interruption are provided in the study manual. 
6.5. Randomization Schedule and Removal of Blind  
There are two separate randomizations in this study; one prior to the start of the double-blind, 
placebo-controlled phase, and one prior to the start of the double-blind, placebo-controlled, 
tirasemtiv  withdrawal phase for all patients .  An IWRS will provide patient randomization 
assignment s for this study.  The site pharmacist or other qualified person responsible for 
randomizing patients will receive the appropriate kit number s through the IWRS and provide it 
to the site staff who will be distributing study drug to the patient.  RANDOMIZATION INFORMATION MAY BE MADE AVAILABLE TO THE INVESTIGATOR ONLY IN THE EVENT OF A MEDICAL EMERGENCY OR AN AE THAT NECESSITATES 
IDENTIFICATION OF THE STUDY DRUG ( tirasemtiv  or placebo) FOR THE WELFARE OF 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 70 THAT PATIENT.  Except in a medical emergency, the Investigator (or designee) and study site 
clinical staff will remain b linded during the conduct of the study and until such time that all 
discrepancies in the clinical database are resolved (i.e., at the time of the database lock).  The 
date/initials and reason for study blind removal by the Investigator and/or clinical staff will be 
documented.  The Investigator will contact the Sponsor as soon as possible before or 
immediately following the emergency unblinding of any patient.  
6.6. Daily Dosing Diary  
A dosing diary will be maintained by the patient to record date and time of twice daily study 
drug administration plus twice daily riluzole  (if taking riluzole ).  The dosing diary should be 
returned at each clinic visit.  
6.7. Study Drug Handling and Disposal   
The site pharmacist or other qualified person responsible for managing study drug supplies will maintain an accurate record of the receipt of the investigational study drug as shipped by the Sponsor (or designee), including the kit number and date received.  One copy of this receipt will 
be returned to the Sponsor when the contents of the investigational study drug shipment have 
been verified.  The study research coordinator or designated study staff will be responsible for patient randomization, using an IWRS.  In addition, an accurate drug disposition record will be 
kept, specifying the kit number provided to each patient and the dates of dose administration.  
This drug accountability record will be available for inspection at any time.  At the completion of the study, the original drug accountability record will be available for review by the Sponsor 
upon request. 
All unused drug supplies will be returned to the Sponsor (or designee) or disposed of by the 
study site, per the Sponsor’s (or designee’s) instructions at the end of the study. 
6.8. Study Drug Accountability  
The patient should be instructed to return all unused study drug to the designated clinical site staff at each study visit.  Study drug accountability is to be conducted by the designated study staff member with the patient at each study visit.  The dosing diaries should al so be referenced 
when completing drug accountability.     
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 71 7. ADVERSE EVENTS  AND SAF ETY ASSESSMENTS  
NOTE: the term “adverse event (AE)” includes both non-serious and serious AEs unless 
otherwise specified.  
The assessment of safety during the course of this study will consist of the surveillance and recording of AEs including SAEs, recording of concomitant medication and measurements of protocol-specific physical examination findings and laboratory tests. 
7.1. Definition s  
7.1.1. Adverse Event  
As defined by the Internationa l Council on Harmonisation (ICH) E2A guideline Definitions and 
Standards for Expedited Reporting, and 21 CFR 312.32, Investigational New Drug ( IND) Safety 
Reporting , an AE is any untoward medical occurrence in a patient or clinical investigation 
subject ad ministered a medicinal  product and which does not necessarily have a causal 
relationship with this treatment.   
Consider the following information when determining whether or not to record a test result, 
medical condition or other incident on the AE eCRF: 
• From the time of informed consent to first administration of study drug (Week -2 
visit), only study protocol- related AEs should be recorded 
• New symptoms or diagnoses reported/found between the time of signing of informed 
consent and the first administratio n of study drug will be recorded as medical history 
on the medical history eCRF 
• Conditions newly detected or diagnosed after administration of study drug, including conditions that may have been present but undetected prior to the start of the study should be recorded  
• All AEs (regardless of relationship to study drug) should be recorded from first 
administration of study drug (Week - 2 visit) through the end of the safety reporting 
period (see Section 7.5, Reporting Period for AEs and SAEs)    
• In general, an abnormal laboratory value should not be recorded as an AE unless it is 
assessed by the Investigator as clinically significant (e.g., associated with clinical 
signs or symptoms, requires intervention, results in a SAE, or results in study 
termination or interruption/discontinuation of study treatment).  When recording an AE resulting from a laboratory abnormality, the resulting medical condition ra ther 
than the abnormality itself should be recorded (e.g., record “thrombocytopenia” rather than “low platelets”)  
• Conditions known to have been present prior to the start of the study that increase in 
severity or frequency aft er administration of study drug should be recorded 
• Signs, symptoms, or the clinical sequelae of a suspected drug interaction should be recorded 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 72 • Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication (overdose per s e should not be 
reported as an AE)  
• New and/or exacerbated symptoms of ALS should be recorded 
Issues Not Considered AEs 
• Medical or surgical procedures (e.g., endoscopy, appendectomy); rather, record the 
medical condition that led to a procedure (e.g., appendicitis ) 
• Situations where an untoward medical occurrence did not occur (e.g., social, diagnostic, or convenience admissions to a hospital)  
• Fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not represent a clinically significant change aft er the first dose of 
study drug 
• Abnormal laboratory or test findings that are not assessed by the Investigator as a clinically significant change aft er the first dose of study drug 
7.1.2. Serious Adverse Events  
An SAE is any AE that  results in any of the following outcomes: 
Death AE resulted in death  
Life threatening  The AE placed the patient at immediate risk of death.  It does not refer to an 
event that hypothetically might have caused death if it were more severe, 
prolonged, or untreated. 
Hospitalization  The AE required or prolonged an existing inpatient hospitalization.  
Hospitalizations for elective medical or surgical procedures or treatments 
planned before the signing of informed consent in the study or routine check-ups are not SAEs by this criterion.  Admission to palliative unit or 
hospice care facility is not considered to be a hospitalization. When in doubt 
as to whether ‘hospitalization’ occurred, consult the Medical Monitor. 
Disability/ 
Incapacity  Resulted in a persistent or significant incapacity or substantial disruption of 
the patient’s ability to conduct normal life functions. This definition is not 
intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (e.g. sprained ankle) that may temporarily interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
Congenital Anomaly/Birth 
Defect An adverse outcome in a child or fetus of a patient exposed to the molecule or study treatment regimen before conception or during pregnancy. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 73 Important 
Medical Event  The AE did not meet any of the above criteria, but could have jeopardized the patient and might have required medical or surgical intervention to 
prevent one of the outcomes listed above.  Examples of such events are 
invasive cancers, intensive treatment i n an emergency room or at home for 
allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospitalization .  The development of drug dependency or drug abuse would 
also be examples of important medical events.   If in doubt as to whethe r or 
not an event qualifies as a “medically significant event”, consult the Sponsor’s Medical Monitor. 
7.2. Adverse Event Severity  
The severity of AEs will be assessed using the National Cancer Institute (NCI) CTCAE, 
version 4.0 as defined  below: 
• Grade 1 (Mild ) – Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
• Grade 2 (Moderate) – Moderate; minimal, local or non -invasive intervention 
indicated; limiting age -appropriate activities of daily living  
• Grade 3 (Severe) – Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self -care activities of daily living   
• Grade 4 ( Life-Threatening) – Life-threatening consequen ces; urgent intervention 
indicated  
• Grade 5 (Fatal) – Death due to AE  
Notes:  
• AE severity and seriousness are assessed independently.  ‘Severity’ characterizes the 
intensity of an AE.  ‘Serious’ is a regulatory definition and serves as a guide to the 
Sponsor for defining regulatory reporting obligations (see definition for Serious AE) 
• Note that “life -threatening” in the criteria for “serious” has a more immediate 
definition than the CTCAE definition of “life- threatening”.  Thus, an AE may be 
CTCAE Grade 4 i n severity and still not meet the SAE definition of “life -
threatening”.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 74 7.3. Assessment of Causality to Study Treatment  
The relationship of each AE to each study treatment [ tirasemtiv ] and [riluzole] should be 
evaluated by the Investigator using the following criteria: 
Related There is evidence to suggest a causal relationship between the drug and the AE, 
such as an event that is uncommon and known to be strongly associated with drug exposure (e.g. angioedema, hepatic injury, Stevens-Johnson Syndrome) an 
event that is not commonly associated with drug exposure, but is otherwise 
uncommon in the population exposed to the drug (e.g. tendon rupture) 
Unrelated  Another cause of the AE is more plausible (e.g., due to underlying disease or occurs commonly in the study population), or a temporal sequence cannot be 
established with the onset of the AE and administration of the study treatment, or a causal relationship is considered biologically implausible 
The assessment of causality will be based on the information avai lable, and may be changed 
upon receipt of additional information. 
7.4. Procedures for Eliciting and Recording Adverse Events  
Investigator and study site personnel will report all AEs and SAEs whether elicited during patient questioning, discovered during physical examination, laboratory testing and/or other 
methods by recording them on the eCRF and/or SAE Form, as appropriate. 
7.4.1. Eliciting A dverse Events  
Use of an open -ended or non-directed method of questioning should be used at each study visit 
to elicit the repo rting of AEs.  
7.4.2. Recording of Adverse Events  
When an AE occurs, the Investigator will review all documentation (e.g., hospital progress notes, 
laboratory and diagnostic reports) relevant to the event.   
The following information should be recorded on the AE  eCRF: 
• Description including onset and resolution dates 
• Whether serious criteria was met  
• Severity 
• Relationship to study treatment 
• Outcome 
7.4.3. Adverse Event Term  
In general, the use of a unifying diagnosis is preferred to the listing out of individual 
signs/symptoms.   Grouping of symptoms into a diagnosis should only be done if each component 
sign and/or symptom is a medically confirmed component of a diagnosis as evidenced by 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 75 standard medical textbooks.  If any aspect of the sign or symptom does not fit into a classic 
pattern of the diagnosis, report the individual symptom as a separate AE. 
7.4.4. Recording Serious Adverse Events  
Record SAE terms on both the AE  eCRF and an SAE Report Form.   The following should be 
considered when recording SAEs: 
• Death is an outcome.  Record the event that resulted in death on both the SAE Form 
and AE eCRF 
• For hospitalizations, surgical, or diagnostic procedures, the illness leading to the 
surgical or diagnostic procedure should be recorded as the SAE, not the procedure 
itself.  Capture the procedure in the narrative description as part of the action taken in 
response to the illness 
7.4.5. Pregnancy  
Complete a Pregnancy Report Form and fax or email the completed form to the Sponsor’s (or 
designee) Drug Safety Department wit hin 24 hours of becoming aware of a pregnancy.  
Pregnancy, per se, will not be considered an AE in this study.  However, a  urine or serum 
pregnancy test should be performed if any female patient or partner of a male patient suspects 
that she has become pre gnant during the time of signing of informed consent to  within 10 weeks 
after the end of the study.  If the test is positive, the pregnancy should be immediately reported to 
the Investigator and Sponsor.  Any patient who becomes pregnant during the study i s not eligible 
to continue in the study and should complete any end of study procedures at that time . 
Complete pregnancy information, including the outcome of the pregnancy, should be collected in the source documents on the female patient or partner of a male patient (if she is willing).  In the 
absence of complications, follow-up after delivery will be no longer than eight  weeks.  Abortion, 
whether accidental, therapeutic, or spontaneous, should be reported as an SAE.  Congenital anomalies or birth defects should also be reported as defined by the ‘serious’ criterion (see 
definitions Section  7.1.2). 
Any SAE occurring as a result of a post -study pregnancy and considered reasonably related to 
the investigational product by the Investigator should be reported to the Sponsor. 
7.5. Reporting Period for Adverse Events  
The safety reporting period for all AEs is from the first administration of study d rug (Week -2 
visit) through 28 days after the patient’s last dose of study drug (Follow-Up V isit).  However, all 
study protocol- related AEs are to be collected from the time of informed consent.  All SAEs that 
occur after the safety reporting period and are considered study drug-related in the opinion of the Investigator should also be reported to the Sponsor.  
All SAEs should be followed until significant changes return to baseline, until the condition 
stabilizes,  or is no longer considered clinically significant by the Investigator,  or until the patient 
dies, withdraws consent, or study closure.  All non-serious AEs will be followed through the 
safety reporting period.  Certain non-serious AEs of interest may be followed until resolution, 
return to baseline, or study closure. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 76 7.5.1. Follow-Up of Adverse Events  
After the initial recording of an AE, the Investigator should proactively follow the patient.  Any 
non-serious AEs that are still on -going at the end of the study should be reviewed to determine if 
further follow-up is required.  The Investigator will document on the AE  eCRF any/all on -going 
non-serious AEs that will not be followed further (and the reason why) after the patient exits the 
study.  If in doubt, the Investigator should consult the Sponsor’s Medical Monitor.   
The Sponsor may request that the Investigator perform or arrange for the conduct of 
supplemental measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of any AE.   
7.6. Serious Adverse Events  Require Im mediate Reporting  
Within 24 hours of the study site’s knowledge of an SAE, Investigators are to report the event to the Sponsor, regardless of relationship of the event to the study drug. 
For initial SAE reports, available details of the event are to be re corded on an SAE Report Form.  
At a minimum, the following should be included: 
• Patient number 
• Date of event onset  
• Seriousness criterion or criteria  
• Description of the event 
• Study treatment  
• Causality assessment  
If not all information regarding an SAE is ini tially available, the site should not wait to receive 
additional information before reporting the event to the Sponsor within 24 hours.   
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 77 8. STATISTICAL METHODS  
8.1. General Considerations  
8.1.1. General Approach  
Summary statistics for continuous variables will include numbers of patients, means, medians, 
standard deviations, standard errors, minima, and maxima.  For categorical variables, frequencies 
and percentages will be given.  For time to event variables, the number of patients at risk, 
number of events, the median and 95% confidence intervals (CI) of the median, and quartiles 
will be provided by Kaplan Meier method.  Assumptions for statistical models will be evaluated.  If assumptions are substantially violated, alternative analysis methods will be considered.  
Missing data will not be imputed unless specified.  Baseline is defined as the last available 
measurement taken before the first dose of study medication received in the open -label phase 
unless otherwise specified.  Analyses will be conducted by study phase including open- label 
phase, first 24-week double blind placebo-controlled phase, 48-week double blind placebo-
controlled phase, randomized withdrawal phase, and follow-up period. 
8.1.2. Sample Size and Randomization 
Approximately 600 p atients will be enrolled in the study.  Following the open- label phase, 
approximately 477 patients will be randomized to placebo and three different target dose levels 
of tirasemtiv  in an allocation ratio of 3:2:2:2 for the double-blind, placebo-controlled treatment  
phase.  The dropout rates at 24 weeks are estimated to be 16% for placebo and 25% for all 
tirasemtiv  target dose groups combined. With a two -tailed alpha error of 0.05, approximately 
360 patients are expected to complete 24 weeks of double-blind treatment,  which is estimated to 
provide 90% power to detect a treatment difference from placebo in percent predicted SVC 
change from baseline to the end of the first 24 week double-blind, placebo-controlled phase of 
6 percentage points for all tirasemtiv  target dose groups pooled with a common standard 
deviation ( SD) of 17 percentage points. 
After patients complete the 48 weeks of the double-blind, placebo- controlled treatment , patients 
will be randomized to placebo or to continue their current active dose level of treatment in an 
allocation ratio of 1:1. Patients who are on placebo will be re -randomized only to placebo  at the 
end of Week 48.  Both randomizations will be stratified by  riluzole use/non-use. 
The common SD  about the primary endpoint (the change from baseline to 24 weeks of the 
double-blind, placebo-controlled phase) will be monitored in a blinded manner.  When one- half 
of the planned completed study patients have been followed for 24 weeks, the common SD of the 
primary endpoint will be calculated on aggregate data with no separation of results by treatment 
group. If this common SD  during the study appears to be larger than 17 percentage points, the 
sample size will be re-estimated with the updated common SD  to maintain the intended study 
statistical power for the primary analysis  using Table 13 .  At this time, the Sponsor may 
consider increasing the sample size.  For example, if the common SD is larger than 17 and equal 
to or less than 18, then consideration will be given to increasing the sample size from 360 evaluable patients  at Week 24  (approximately 477 randomized patients) to 421 evaluable patients 
at Week 24  (approximately 540 randomized patients). 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 78 Table 13: Sample Size Re- estimation Depending on Common SD at Week 24  
Common SD at Week 24 >17-18 >18-19 >19-20 
Total Number of Randomized Patients  540 594 666 
Total Number of Evaluable Patients at Week 24  421 463 519 
8.1.3. Data Monitoring Committee 
An independent DMC ( see Section 5.16) will periodically assess patient safety in an unblinded 
manner during the course of the study. The independent DMC will be provided unblinded data 
by an independent unblinded statistician from an  independent biostatistical group.  The DMC 
activities are described in the DMC charter.  
8.2. Analysis Sets 
8.2.1. Full Analysis Set (FAS)  
The FAS will consist of all randomized patients who received at least one dose of study medication during randomized double-blind, placebo- controlled treatment, and had at least one 
post-randomization e fficacy assessment.  The FAS will be analyzed as randomized.  
8.2.2. Per Protocol Set (PPS)  
The PPS will consist of all FAS patients who complete a minimum of 20 weeks of double-blind, placebo-controlled treatment, have at least one post -baseline efficacy assessment during 
treatment with double -blind study drug, and have no major protocol violations. 
8.2.3. Safety Analysis Set (SAS)  
The SAS will consist of all patients who receive any study med ication, including patients in the 
open-label phase.  
8.2.4. Pharmacokinetic Evaluable Data Set (PK EDS) 
The PKEDS will consist of all randomized patients with at least one evaluable PK concentration, 
provided they have no major protocol violations that could affect the PK of tirasemtiv  or riluzole. 
8.3. Efficacy Endpoints  
8.3.1. Primary Endpoint  
The primary endpoint is the change from baseline to Week 24 of the double-blind, placebo-controlled phase in percent predicted SVC.  The primary analysis will be conducted using all 
observed data during the randomized, double-blind, placebo-controlled phase without any missing data imputations and will be based on the FAS.  To minimize the potential for missing data, patients who wish to discontinue study drug will be encouraged to continue study 
assessments and at minimum present for the 24 week assessments.  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 79 8.3.2. Secondary Endpoints  
The followi ng secondary endpoints will be analyzed in a closed testing procedure if the primary 
efficacy analysis is met as defined in Section 8.4.3. 
• Change fro m baseline in the ALSFRS -R score of the three respiratory items of the 
ALSFRS-R (i.e., the sum of items 10,  11 and 12) at the end of 48 weeks of double-blind, 
placebo-controlled treatment 
• Slope of mega-score of muscle strength during the 48 weeks of double-blind, placebo-
controlled treatment  
• Time to the first occurrence of a decline from baseline in percent predicted SVC ≥20 percentage points or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-controlled t reatment 
• Time to the first occurrence of a decline in SVC to ≤50% predicted or the onset of respiratory insufficiency or death at the end of the 48 weeks of double-blind, placebo-
controlled treatment  
• Change from baseline in the ALSFRS -R total score to the end of 48 weeks of the double-
blind, placebo- controlled treatment  
• Time to the first use of mechanical ventilatory assistance or death during all 48 weeks of double-blind, placebo- controlled treatment  
8.3.3. Tertiary Endpoints  
Tertiary endpoints are presented grouped by their similarities to one another.  The prospectively 
defined tertiary  endpoints listed below will be the subject of descriptive, exploratory analyses as 
defined in the Statistical Analysis Plan.   Additional tertiary endp oints of interest may be added to 
the Statistical Analysis Plan.  
1. “Time to Event” analyses including:  
a. Time to the first occurrence of a decline in SVC to ≤ 50% predicted or the onset of 
respiratory insufficiency (defined as tracheostomy or the use of non- invasive 
ventilation for ≥ 22 hours per day for ≥ 10 consecutive days) or death during the first 
24 weeks of double-blind, placebo- controlled treatment 
b. Time to the first occurrence of a decline from baseline in percent predicted SVC 
≥ 10 percentage points or the onset of respiratory insufficiency or death during the first 24 weeks of double-blind, placebo- controlled treatment  
c. Time to the first occurrence of a decline from baseline in percent predicted SVC 
≥ 20 percentage points or the onset of respiratory insufficiency or death during the first 24 weeks of double-blind, placebo- controlled treatment  
d. Time to the first occurrence of a decline in the respiratory components of the 
ALSFRS-R (i.e., items 10, 11, and 12) or death during the first 24 weeks of double-
blind, placebo- controlled treatment  
e. Time to the first occurrence of a decline in either of the ALSFRS -R items 11 or 12 or 
death during the first 24 weeks and during all 48 weeks of double-blind, placebo-controlled treatment  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 80 f. Time to the first occurrence of a decline in either of the ALSFRS -R item 12 or death 
during the first 24 weeks and during all 48 weeks of double-blind, placebo-controlled 
treatment  
g. Time to the first occurrence of the first use of mechanical ventilatory assistance or 
death during the first 24 weeks of double-blind, placebo- controlled treatment 
In addition, each of the first three composite endpoints listed above will be analyzed with “first 
use of mechanical ventilatory assistance” in place of “respiratory insufficiency”.  
2. “Responder analyses” including: 
a. Proportion of patients with no decline from baseline in percent predicted SVC, free 
from respiratory insufficiency and alive during the first 24 weeks and during all 48 weeks of double-blind, placebo- controlled treatment 
b. Proportion of patients with a decline from baseline ≤ 6 percentage points in percent predicted SVC, free from respiratory insufficiency and alive during the first 24 weeks and during all 48 weeks of double-blind, placebo- controlled treatment  
c. Proportion of patients with a decline from baseline ≤ 10 percentage points in percent predicted SVC, free from respiratory insufficiency and alive during the first 24 weeks and during all 48 weeks of double-blind, placebo- controlled treatment  
d. Proportion of patients with a decline from baseline ≤ 20 percentage points in percent predicted SVC, free from respiratory insufficiency and alive during the first 24 weeks and during all 48 weeks of double-blind, placebo- controlled treatment  
3. Change from basel ine to 24 weeks of double-blind, placebo -controlled treatment in the 
following measures:  
a. ALSFRS-R total score  
b. ALSFRS-R score of the three respiratory subdomains of the ALSFRS- R 
(i.e., items  10, 11, and 12) 
c. Muscle strength as determined by the mega -score of: 
• Elbow flexion (bilateral)  
• Wrist extension (bilateral)  
• Knee extension (bilateral)  
• Ankle dorsiflexion (bilateral)  
• Handgrip strength (bilateral)  
d. SNIP 
4. Slopes of the changes from baseline in percent predicted SVC, ALSFRS- R, mega-score 
of muscle strength, and SNIP: 
a. From baseline to 24 weeks of the randomized, double-blind, placebo-controlled phase  
b. From baseline to 48 weeks of the randomized, double-blind, placebo-controlled phase 
(excluding mega- score of muscle strength)  
c. From the end of 24 weeks of the randomized, double-blind, placebo-controlled phase to the end of the double-blind, randomized, placebo-controlled phase at 48 weeks 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 81 5. Change in percent predicted SVC,  muscle strength mega -score, and SNIP from baseline 
to the end of Week 48 of the double-blind, placebo -controlled phase. 
6. Change in percent predicted SVC from baseline to the end of Week 12 of the double-
blind, placebo -controlled phase. 
8.3.4. Additional Endpoints  
1. ALSAQ-5 change from baseline to the end of Week 24 
2. Epworth Sleepiness Scale change from baseline to the end of Week 24   
3. Caregiver burden change from baseline to the end of Week 24 
4. ALSAQ-5 change from baseline to the end of Week 48 
5. Epworth Sleepiness Scale change from baseline to the end of Week 48  
6. Caregiver burden change from baseline to the end of Week 48 
8.4. Statistical Anal yses 
8.4.1. Patient Disposition  
The number of patients who are enrolled and receive open- label treatment but are not 
randomized will be presented.  The number of patients who are randomized, who receive any 
double-blind study medication, who complete the study, and who prematurely discontinue from the study will be presented by treatment group and target  dose level overall and for each phase 
separately.  Reasons for premature discontinuation as recorded on the termination page of the eCRF will be summarized by tre atment group and target dose level overall and for each phase 
separately.  
8.4.2. Demographics and Other Baseline Characteristics  
Patient demographics and other baseline characteristics will be summarized by treatment group and target dose level overall and by pha se separately.  To assess the comparability of treatment 
groups, demographic and baseline characteristics will be compared between the pooled active 
treatment dose levels and placebo for the FAS using Cochran- Mantel-Haenszel tests for binary 
categorical variables, van Elteren tests for ordinal categorical measures, or analysis of variance 
(ANOVA) for continuous variables, stratified by riluzole use/non-use and pooled site. 
A demographic or baseline disease characteristic found to have a statistically significant (2 -sided 
p-value ≤ 0.050) imbalance between the two treatment groups will be adjusted in supportive 
analyses of the primary efficacy endpoint.  
8.4.3. Primary Efficacy Analysis 
The primary analysis is to test the global null hypothesis that there is no treatment difference in 
the change from baseline in percent predicted SVC at Week 24  between patients in the FAS 
randomized to placebo and those randomized to tirasemtiv  (pooled three target dose levels) 
during the placebo-controlled double- blind treatment.  The analysis will be performed using a 
repeated-measures mixed model which will include terms of treatment, baseline, pooled center, 
visit, and riluzole  use/non-use as well as interaction terms of treatment -by-visit and baseline- by-
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 82 visit with an unstructur ed covariance matrix , using all observed data during the 24- week, double -
blind, placebo-controlled phase without any missing data imputations .  The treatment variable 
will be introduced to the mixed model with 4 categories including placebo and the three t arget 
dose levels.  The difference in the primary endpoint of the overall tirasemtiv  effect relative to 
placebo will be calculated  in an estimate statement.   
The sites will be pooled by country and then by criteria to be determined if there are more than 
40 patients enrolled in one country.  The detailed algorithm will be determined and submitted to 
the regulatory authorities after the enrollment completes  and before the database lock  for 
Week 24 placebo-controlled phase.  
8.4.4. Supportive Efficacy Analyses  
As a key supportive analysis, the primary efficacy endpoint will be analyzed for the FAS using 
rank transformation repeated measures analysis of covariance (ANCOVA) including the same 
terms in the primary efficacy analysis.  Ranks will be applied to all obser ved changes from 
baseline (regardless of visits) for continuous variables in the model in case large variance 
heterogeneity or inflation of variance from extreme outliers  is observed.  Based on the extent of 
outliers in the blinded data review when all pat ients complete the treatment at Week 24 before 
database lock, the rank -based analysis (or a more rigorous randomized-based version for within 
visit rankings) will be conducted.   
As supportive analyses, the primary efficacy endpoint will be analyzed for the FAS and the PPS 
using the same method as the primary efficacy analysis, including terms of unbalanced baseline characteristics and the treatment -by-factor interactions.  
8.4.5. Secondary and Tertiary Efficacy Analyses 
All analyses will be performed with the methods below for all secondary or tertiary endpoints for 
the first 24-week double-blind placebo-controlled phase and the 48-week double-blind placebo-
controlled phase separately.  For endpoints related to skeletal m uscle function, the interaction of 
treatment -by-riluzole will also be included in the models.  
Secondary or tertiary endpoints of change from baseline parameters will be analyzed using the 
same method as the primary efficacy analysis.  
For binary variables , the proportion of patients with an event will be provided.  Odds ratios and 
their 95% CIs as well as p -values will be calculated using conditional logistic regression for 
treatment difference between tirasemtiv  and placebo, stratif ied for pooled site wit h terms of 
baseline, treatment, and riluzole use/non-use in the model.  
For time to event variables, a proportional hazards Cox regression model will be used to estimate 
the hazards ratio and its 95% CI  between the two treatment groups, including treatment and 
covariates of baseline SVC value, pooled site, and riluzole use/non-use.  
Slope endpoints will be analyzed using a mixed model which will include treatment, the baseline value, pooled site, time, and riluzole  use/non-use as well as interaction terms o f treatment -by-
baseline, treatment -by-time, assuming random slope effect. Slope endpoints will be compared 
between the patients randomized to  all tirasemtiv  target dose levels during the double-blind, 
placebo-controlled phase and the patients who were randomized to placebo during the double-
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 83 blind, placebo-controlled phase for the first 24-week double-blind placebo-controlled phase and 
the 48-week double-blind placebo-controlled phase separately . 
8.4.6. Other Supportive  Efficacy Analyses  
The potential for a rebound effect following withdrawal of tirasemtiv  (i.e., acute worsening of 
function to a degree significantly worse than the decrement over time associated with placebo 
treatment) will be assessed by comparing the change from baseline to 49 weeks and from 
baseline to 52 weeks for all primary , secondary , and tertiary change from baseline endpoints on 
tirasemtiv  (48 weeks of double-blind placebo -controlled phase) /placebo (4 weeks of randomized 
withdrawal phase)  versus placebo (48 weeks of double-blind placebo -controlled phase)/ placebo 
(4 weeks of randomized withdrawal phase) for the randomized withdrawal phase. The  95% CIs 
will be ca lculated for the difference in LSM between the placebo/placebo group and the 
tirasemtiv /placebo group.  
8.4.7. Additional Efficacy Analyses  
Additional efficacy analyses based on the change from baseline of additional efficacy endpoints will be analyzed using the same method as described for the primary efficacy  analysis in the 
FAS.  
8.4.8. Hypothesis Testing and M ultiplicity  
The null hypothesis for the primary and secondary efficacy endpoints will be tested in a pre-specified order using a closed testing procedure.  This procedure will maintain the family- wise 
error rate at two-sided significance level  of 0.05 for all hypotheses tested in a confirmatory 
sense.  The methodology of the closed testing procedure is fully described in the statistical 
analysis plan.   
Comparisons of dose groups for the primary and secondary endpoints will be considered 
exploratory and used to supportively confirm which driving dose(s) that has the effect on these 
endpoints versus placebo.   
8.4.9. Sensitivity Analysis  
Several sensitivity analyses will be conducted.  First, the primary efficacy analysis will be 
repeated using multiple imputations with the Markov chain Monte Carlo method to impute 
missing data points for the actual change from baseline in percent predicted SVC .  After the 
multiple imputations under a missing at random paradigm, imputed values subsequent to death 
will be set to 50% wo rse than the values produced from the multiple imputations.  The sensitivity 
analysis for the base case will use the change from baseline of all observed and the 
aforementioned imputed data in the primary analysis model.  Two additional sensitivity analyse s 
will be conducted using the invocations of such multiple imputations with 5% and 10% pessimism for the imputed missing values at each visit for the active treatment group.  When 
imputed data no longer have compatibility with parametric assumptions, ANCOVA based on 
ranks subsequent to imputations will be used.  Second, the primary efficacy analysis will be 
repeated in all randomized patients in the first 24 week s of placebo-controlled phase. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 84 8.4.10. Subgroup Efficacy Analyses 
Analyses of the primary efficacy endpo int and the secondary endpoints evaluating the c hange 
from baseline in the ALSFRS- R score of the three respiratory items of the ALSFRS -R at the end 
of 48 weeks of double-blind, placebo-controlled treatment and the slope of mega- score of muscle 
strength during the 48 weeks of double-blind, placebo- controlled treatmen t phase will be 
conducted in subgroups based on the medians of percent predicted SVC , body weight, and BMI 
at baseline, r iluzole use/non-use, baseline ALSFRS -R, time since first symptom, time sin ce 
diagnosis of ALS, by randomized target dose level, by actual maintenance dose established 
during the double-blind placebo-controlled phase, sex, age group (<65, > 65 years old), race, 
geographic region (i.e., Europe versus North America), anatomic site of disease onset (bulbar 
versus limb), and other subgroups as may be specified in the SAP, in the FAS.  The reduced 
sample size within each subgroup will reduce the power of the statistical tests, so significant 
treatment effects within each subgroup are not expected.  
8.5. Safety Analysis 
Safety analyses will be based on the SAS overall and by the phases of the study (i.e., open -label 
phase; the first 24 weeks of the double-blind, placebo -controlled phase; all 48 weeks of the 
double-blind, placebo -controlled pha se; the double-blind, placebo -controlled tirasemtiv  
withdrawal phase; and until the end of the follow-up period as well as subgroup analyses by 
riluzole use/non-use . 
8.5.1. Adverse Events  
A TEAE is an AE with an onset after initiation of study drug dosing, or an AE present at 
initiation of study drug dosing that worsens in severity after initiation of study drug dosing.  AE s 
will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) Preferred 
Terms and grouped by System Organ Class.  The version of the MedDRA dictionary will be 
noted in the report.  AEs  will be classified according to CTCAE grade.  
TEAEs will be assigned to the open- label phase treatment, to the randomized target dose level, 
or to the dose level administered immediately prior to the onset of the TE AE during the double-
blind treatment.   TEAEs that begin during the open-label phase but continue without an increase 
in severity after randomization into the double-blind, placebo -controlled, treatment phase will be 
assigned to the randomized, double- blind treatment only if they persist without an increase in 
severity beyond 96 hours after the first dose of double-blind, placebo-controlled study medication.  In BENEFIT- ALS, this convention minimized the assignment to double-blind 
placebo of those TEAEs that began during treatment with open-label tirasemtiv  but resolved 
shortly after the initiation of treatment with double -blind placebo while appropriately assigning 
to double-blind tirasemtiv  those TEAEs that began during treatment with open- label tirasemtiv  
that continued past the initiation of treatment with double -blind tirasemtiv . 
If a TEAE continues after a change in dose level without an increase in intensity, it will be 
assigned only to the dose level at which it initiated.  If a TEAE  continues and worsens in 
intensity after a change in dose level, it will be assigned both to the dose level at which it initiated and to the dose level at which it worsened.  If a TEAE resolves during continued treatment at the same dose level at which it  initiated but then recurs following a change in dose 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 85 level, it will be assigned both to the dose level at which it initiated and resolved and again at the 
dose level at which it re -initiated.   
The number and percentage of patients with TEAEs will be summarized by system organ class, 
preferred term, dose level, and treatment overall and by phase.  The number and percentage of patients reporting TEAEs will be tabulated by system organ class, preferred term, dose level, 
treatment, and severity o verall and by phase.  On patient -based AE tables, for a specific TEAE, 
the patient will be counted only once under the most severe grade if the TEAE is reported more 
than once per patient per dose level and treatment.  The above AE  summaries will also be 
performed by riluzole use and non-use.  Additionally, the number and percentage of patients with 
TEAEs will be summarized for the open -label phase, by system organ class, preferred term, 
comparing patients who later received active tirasemtiv  to those who r eceived placebo during the 
randomized double-blind treatment.  Further tabulation by severity for the open- label phase will 
also be provided.  Similar TEAE summaries will be provided for the double-blind, placebo-
controlled phase and the tirasemtiv  withdrawal phase as well.  The above TEAE summaries will 
be repeated by randomized treatment and dose level.  
Only TEAEs occurring from the first dose through 28 days after the last dose of study drug will 
be summarized.  All AEs will be included in patient listings.  
8.5.2. Other Safety Assessments  
The death incidence density will be provided by treatment group, adjusting for patients’ actual treatment duration.  The ratio of death incidence density and 95% CI in tirasemtiv  relative to 
placebo will be calculated u sing Poisson regression.  Weight change from baseline will be 
evaluated by using the same method as the primary analysis.  Clinical laboratory data, vital signs, 
ECGs, neurological exams, physical exams, and falls assessments will be descriptively summarized by dose level and treatment overall and by phase.  
8.5.3. Suicidality Assessments  
Suicidality ideation and its intensity will be summarized descriptively by treatment and dose level overall and by phase.  
8.6. Study Drug Exposure  
Study drug exposure will be summarized.  The distribution of exposure by randomized dose 
level will be tabulated overall and by phase.  
8.7. Concomitant Medication  
Concomitant medications taken between seven days prior to the first dose of study drug 
throughout 28 days after the last dose of study drug will be summarized and classified by drug 
class and preferred name by treatment, dose levels overall and for each study phase, using the World Health Organization ( WHO) Drug dictionary in the most current version when the study 
enrollment sta rts.  The version of the WHO Drug dictionary will be noted in the clinical study 
report. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 86 8.8. Pharmacokinetic Analysis  
PK analysis will be based on the PK EDS.  Descriptive statistics (arithmetic mean, SD, median, 
minimal, maximum, geometric mean, and coefficient of variation) will be presented for the 
concentration of  tirasemtiv , its metabolites , and for riluzole by treatment group and study visit.   
8.9. Pharmacodynamic Analysis  
Pharmacodynamic ( PD) analysis may be performed to explore the relationship between 
tirasemtiv  exposure and efficacy and safety endpoints.   
8.10. Change in Statistical Methods  
All changes in statistical methods that are described in the statistical analysis plan will be 
documented in the clinical study report. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 87 9. ADMINISTRATIVE ASPECTS 
9.1. Change in Protocol  
There will be no alterations in the protocol without agreement between the Sponsor and the 
Principal Investigator (PI).  
There will be no alterations in the protocol without the express written approval of the Sponsor, 
Investigator, and the IRB/ EC/REB (see Form FDA 1572). 
9.2. Initiation Visit  
Prior to the start of the clinical study, the representative(s) of the Sponsor will meet with the 
Investigator(s) and appropriate clinical staff to familiarize the Investigator and clinical staff with 
the materials  necessary for conducting the clinical study.  
9.3. Disclosure  
All information provided regarding the study, as well as all information collected/documented 
during the course of the study, will be regarded as confidential.  The Investigator agrees not to disclose such information in any way without prior written permission from the Sponsor. 
Any publication of the results, either in part or in total (e.g., articles in journals or newspapers, 
oral presentations, abstracts, etc.) by the Investigator(s) or their representative(s), shall require 
prior notification and review, within a reasonable time frame, by the Sponsor, and cannot be 
made in violation of the Sponsor’s confidentiality restrictions or to the detriment of the 
Sponsor’s intellectual property rights. 
9.4. Monitoring  
The Sponsor will designate site monitors who will be responsible for monitoring this clinical 
trial.  The site monitor will monitor the study conduct, proper eCRF and source documentation 
completion and retention, and accurate study drug accountability.  To this end, the monitor will 
visit the study site at suitable intervals and be in frequent contact through verbal and written 
communication.  It is essential that the site monitor have access to all documents (related to the 
study and the individual participants) at any time these are requested.   In turn, the site monitor 
will adhere to all requirements for patient confidentiality as outlined in the ICF.  The Investigator 
and other study personnel will be expected to cooperate with the site monitor, to be available during a portion of the monitoring visit to answer questions, and to provide any missing information. 
9.5. Institutional Review Board / Ethics Committee  / Research Ethics 
Board 
In accordance with the US Code of Federal Regulations, 21 CFR 56, the protocol, advertisement 
(if applicable), and ICF will be submitted to the IRB/EC/REB  for review and subsequent written 
approval by the IRB/ EC/REB must be received before proceeding.  The Sponsor will supply 
relevant material for the Investigator to submit to the IRB/EC/REB  for the protocol’s review and 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 88 approval.  Verification of the IRB/ EC/REB unconditional approval of the protocol and the 
written ICF statement will be transmitted to the Investigator.  
The IRB/EC/REB will be informed by the Investigator of subsequent protocol amendments and 
of serious and unexpected AEs.  Approval for protocol amendments will be transmitted in 
writing to the Investigator.  If requested, the Investigator will permit audits by the IRB/EC/REB  
and regulatory inspections by providing direct access to source data/documents. 
The Investigator will provide the IRB/ EC/REB with progress reports at appropriate intervals (not 
to exceed one year) and a Study Progress Report following the completion, termination, or 
discontinuation of the Investigator’s participation in the study.  
9.6. Informed Consent  
Written informed consent for the study will be obtained from all patients before protocol- specific 
procedures are carried out.  The ICF generated by the Investigator (or designee) will be app roved 
(along with the protocol) by the IRB/ EC/REB and will be acceptable to the Sponsor. 
The Investigator (or designee) will explain the nature of the study and the action of the test 
product.  The patients will be informed that participation is voluntary and that they can withdraw 
from the study at any time.  In accordance with 21 CFR 50, informed consent shall be 
documented by the use of a written ICF approved by the IRB/ EC/REB and will be signed by the 
patient prior to protocol- specific procedures being performed.   The patient will be given a copy 
of the signed consent, and the original will be maintained with the patient’s records.  A copy of 
the IRB/EC/REB-approved site-specific ICF must be sent to the Sponsor (or designee).   
9.7. Records 
The results from data collected during the study will be recorded in the patient’s eCRF.  To 
maintain confidentiality, the patients will be identified only by numbers.  
The completed eCRFs will be transferred to the Sponsor or designee.  All source documents, records, and reports will be retained by the study site in accordance with 21 CFR 312.62(c).  All primary data, or copies thereof (e.g., laboratory records, source documents, correspondence, 
photographs, and computer records), which are a result of the original observat ions and activities 
of the study and are necessary for the reconstruction and evaluation of any study report, will be 
retained in the study site archives.  
9.8. Reference to Declaration of Helsinki/Basic Principles  
The study procedures outlined in this protocol will be conducted in accordance with the CFR governing Protection of Human Subjects (21 CFR 50), Financial Disclosure by Clinical Investigators (21 CFR 54), IRBs (21 CFR 56), Investigational New Drug Application 
(21 CFR 312), and Applications for FDA Approval to Market a New Drug (21 CFR 314), as 
appropriate.  As such, these sections of U.S. Title 21 CFR, along with the applicable ICH 
Guidelines, are commonly known as Good Clinical Practices (GCP), which are consistent with 
the Declaration of Helsinki, 1996. 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 89 10. REFERENCES  
Hwee, D., A. Kennedy, et al. (2014) "Fast Skeletal Muscle Troponin Activator tirasemtiv 
Increases Muscle Function and Performance in the B6SJL -SOD1G93A ALS Mouse 
Model." PLoS One DOI: 10.1371/journal.pone.0096921. 
Kiernan, M., S. Vucic, et al. (2011). "Amyotrophic lateral sclerosis." Lancet 377(9769): 942-
955. 
Lacomblez, L., G. Bensimon, et al. (1996). "Dose -ranging study of riluzole in amyotrophic 
lateral sclerosis." The Lancet  347: 1425-1431. 
Russell, A., J. Hartman, et al. (2012). "Activation of fast skeletal muscle troponin as a potential 
therapeutic approach for treating neuromuscular diseases." Nat Med  18(3): 452-455. 
Tinetti, M., D. Baker, et al. (2004). The Victorian Quality Council Guidelines for Minimising the 
Risk of Falls &Fall- related Injuries. Reducing the risk of falls among older adults in the 
community , Peacable Kingdom Press.  
 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 90 APPENDIX A. SCHEDULE OF EVENTS 
Procedure  Screening  Open-
Label 
Phase Double-Blind, Placebo Controlled Phase  Double-Blind, 
Placebo-Controlled, 
Tirasemtiv  
Withdrawal Phase Follow- 
Up 
Week -4 Week -2 Day 1 Week 2 Week 4 Week 8 Week 12 Week 16 Week 20 Week 24 Week 32 Week 40 Week 48 Week 49 Week 52 Week 56 
Informed Consent  X                
Inc/Exc Criteria  X                
Demographic Data  X                
Medical History1 X                
Physical Examination  X         X   X   X 
Neurological Exam  X         X   X   X 
Ashworth Score  X    X X X   X   X   X 
Concomitant Meds  X X X X X X X X X X X X X X X X 
12-lead ECG  X     X    X   X  X X 
Vital Signs2 X X X X X X X X X X X X X X X X 
Clinical Safety Labs3 X X   X X    X   X  X X 
Serum Pregnancy4 X         X       
PK Sample   X X  X X  X  X X X X X X  
Biomarker Sample    X   X  X  X X X X    
ALSFRS-R X X X  X X X X X X X X X X X X 
Handgrip Strength   X   X X X X X X X X X X X X 
Respiratory Assessment  X X X  X X X X X X X X X X X X 
Muscle Strength   X   X X X X X X X X X X X X 
ALSAQ-5  X     X   X   X   X 
Epworth Sleepiness Scale   X     X   X   X   X 
Suicidality Assessment  X X X X X X X X X X X X X X X X 
Caregiver Burden   X        X   X   X 
Falls Assessment   X X X X X X X X X X X X X X X 
AE Assessment   X X X X X X X X X X X X X X X 
Randomization    X          X    
Study Drug Dosing   X X X X X X X X X X X X X   
Riluzole Dosing5  X X X X X X X X X X X X X   
Phone Contact   X6               
1 Includes smoking history  
2 Weight obtained at each visit   
3 TSH only at screening visit 
4 Serum pregnancy test only for females of child bearing potential  
5 Riluzole dosing if applicable for patients currently taking riluzole  
6 Phone contact with patient after 7 days of open-label tirasemtiv  
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 91 APPENDIX B.  SUBSTRATES OF CYP2B6, 2C8 , 2C9, AND 2C19 
2B6 2C8 2C9 2C19 
artemisinin  amodiaquine  NSAIDs:  PPIs: 
bupropion  cerivastatin  diclofenac  esomeprazole  
cyclophosphamide  paclitaxel  ibuprofen  lansoprazole  
efavirenz repaglinide  lornoxicam  omeprazole  
ifosphamide  sorafenib meloxicam  pantoprazole  
ketamine torsemide  S-naproxen→Nor  Anti-epileptics:  
meperidine   
piroxicam  diazepam→Nor  
methadone   
suprofen phenytoin(O)  
nevirapine   
Oral Hypoglycemic 
 S-mephenytoin  
propafol  
tolbutamide  phenobarbitone  
selegiline   
glipizide Other: 
sorafenib  
Angiotensin II Blockers:  amitriptyline    
losartan carisoprodol    
irbesartan  citalopram    
Sulfonylureas:  chloramphenicol    
glyburide  clomipramine    
glibenclamide  clopidogrel    
glipizide cyclophosphamide    
glimepiride  hexobarbital    
tolbutamide  imipramine N -DeME   
Other: indomethacin    
amitriptyline  labetalol   
celecoxib  R-mephobarbital    
fluoxetine  moclobemide    
fluvastatin  nelfinavir    
glyburide  nilutamide    
nateglinide  primidone    
phenytoin -4-OH progesterone    
rosiglitazone  proguanil    
tamoxifen  propranolol    
torsemide  teniposide    
valproic acid  R-warfarin→8 -OH   
S-warfarin voriconazole    
zakirlukast   
http://medicine.iupui.edu/clinpharm/ddis/main -table/ 
Protocol CY 4031   CONFIDENTIAL  
Version: 26 June 2017  Page 92 APPENDIX C. SUBSTRATES, INHIBITORS AND INDUCERS OF CYP1A2 
Substrates  Inhibitors  Inducers  
amitriptyline  fluvoxamine***  broccoli 
caffeine ciprofloxacin***  brussel sprouts  
clomipramine  cimetidine*  carbanazepine  
clozapine  amiodarone  char-grilled meat  
cyclobenzaprine  efavirenz insulin 
duloxetine  fluoroquinolones  methylcholanthrene  
estradiol fluvoxamine  modafinil  
fluvoxamine  furafylline  nafcillin 
haloperidol  interferon  beta-naphthoflavone  
imipramine N -DeMe methoxsalen  omeprazole  
mexiletine  mibefradil  rifampin 
nabumetone  ticlopidine  tobacco 
naproxen   
olanzapine    
ondansetron    
phenacetin1    
acetaminophen→NAPQI    
propranolol    
riluzole   
ropivacaine    
tacrine   
theophylline    
tizanidine    
triamterene    
verapamil    
(R)warfarin    
zileuton   
zolmitriptan    
***strong inhibitor, *weak inhibitor  
http://medicine.iupui.edu/clinpharm/ddis/main -table/ 